{
  "llama2:latest": [
    {
      "question_id": 1,
      "question": "What is the recommended first-line therapy for lipid lowering in patients with chronic coronary disease (CCD), and what is the target LDL-C reduction?",
      "answer": "The recommended first-line therapy for lipid lowering in patients with chronic coronary disease (CCD) is high-intensity statin therapy. The target LDL-C reduction is at least 50% from baseline levels, and ideally <1.4 mmol/L (55 mg/dL). This is based on the evidence from 38 randomized controlled trials (RCTs) that established the efficacy and safety of high-intensity statin therapy in reducing cardiovascular morbidity and mortality rates. The Clinical Guidelines on the Management of Blood Cholesterol, published by the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, recommend that high-intensity statin therapy be prescribed up to the highest tolerated dose to reach the LDL-C goals set for the specific risk group.",
      "ground_truth": "Statins remain first-line therapy for lipid lowering in patients with CCD. The aim with high-intensity statin therapy is to achieve a \u00e2\u2030\u00a550% reduction in LDL-C levels to reduce the risk of major adverse cardiovascular events (MACE). For patients in whom high-intensity statin therapy is contraindicated or not tolerated, moderate-intensity statin therapy is recommended with the aim of achieving a 30% to 49% reduction in LDL-C levels.",
      "context": "The expected LDL-C reductions in response to therapy are\nshown in Figure 13, and may vary widely among individuals.\nTherefore, monitoring the effect on LDL-C levels is recommended,\nwith assessment of LDL-C levels 4 - 6 weeks after any treatment\nstrategy initiation or change.\nTreatment Average LDL-C reduction\nIntensity of lipid-lowering treatment\nModerate-intensity statin\nHigh-intensity statin\nHigh-intensity statin plus ezetimibe\nPCSK9 inhibitor\nPCSK9 inhibitor plus high-intensity statin\nPCSK9 in...",
      "latency_seconds": 79.08289861679077,
      "token_count": 145.6,
      "throughput_tokens_per_sec": 1.8411060108649888,
      "cosine_similarity": 0.5158910929809425,
      "precision": 0.5,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.23529411764705882,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 112,
      "ground_truth_length_words": 66,
      "length_ratio": 1.696969696969697,
      "has_hallucination": false
    },
    {
      "question_id": 2,
      "question": "When is long-term beta-blocker therapy NOT recommended for improving outcomes in patients with chronic coronary disease?",
      "answer": "Long-term beta-blocker therapy is NOT recommended for improving outcomes in patients with chronic coronary disease (CCD) without previous myocardial infarction (MI) or left ventricular systolic dysfunction. This is based on the provided medical documents, which state that \"the strongest data for the beneficial effects of beta-blocker therapy in CCD is for patients with LV systolic dysfunction.\" The documents also mention several ongoing randomized controlled trials (RCTs) aimed at evaluating the need and duration of beta-blocker therapy for reducing major adverse cardiovascular events (MACE) among post-MI patients with preserved LV systolic function.\n\nSpecifically, the documents state that \"patients with CCD comprise patients with or without previous MI, LV systolic dysfunction, or both.\" Therefore, if a patient does not have a history of MI or LV systolic dysfunction, long-term beta-blocker therapy may not be beneficial for improving outcomes.\n\nTo illustrate this point, the documents provide statistics from the REACH registry, which evaluated patients with CAD without a history of MI. The analysis found that \"among patients with CAD without history of MI, the use of beta-blocker therapy was not associated with a significant reduction in event rates for the primary endpoint.\"\n\nIn conclusion, based on the provided medical documents, long-term beta-blocker therapy is NOT recommended for improving outcomes in patients with chronic coronary disease without previous myocardial infarction or left ventricular systolic dysfunction.",
      "ground_truth": "Long-term beta-blocker therapy is not recommended to improve outcomes in patients with CCD in the absence of myocardial infarction in the past year, left ventricular ejection fraction \u00e2\u2030\u00a450%, or another primary indication for beta-blocker therapy (such as angina, uncontrolled hypertension, or arrhythmias).",
      "context": "era. Other primary indications for beta blockers may\ninclude their use for angina, uncontrolled hypertension,\nor arrhythmias. A comprehensive screening as well as\nassessment of their symptoms and comorbid conditions\nis recommended given that beta-blocker therapy may still\nbe indicated for its antianginal properties (see Section\n4.3.6 ), antihypertensive properties (see Section 4.2.7 ,\n\u201cBlood Pressure Management \u201d), or for its negative chro-\nnotropic effects among patients with rhythm disturbance...",
      "latency_seconds": 108.5720145702362,
      "token_count": 287.3,
      "throughput_tokens_per_sec": 2.6461699282013695,
      "cosine_similarity": 0.48417441831444175,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.15384615384615385,
      "entity_overlap_truth": 0.5,
      "answer_length_words": 221,
      "ground_truth_length_words": 42,
      "length_ratio": 5.261904761904762,
      "has_hallucination": true
    },
    {
      "question_id": 3,
      "question": "For patients with CCD and type 2 diabetes, what two classes of glucose-lowering medications are recommended to reduce cardiovascular risk?",
      "answer": "For patients with CCD and type 2 diabetes, the two classes of glucose-lowering medications that are recommended to reduce cardiovascular risk are SGLT2 inhibitors and GLP-1 receptor agonists.\n\nAccording to the provided medical documents, both medication classes have been shown to significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and CCD. Specifically:\n\n* SGLT2 inhibitors have been found to reduce the risk of MACE by 15-30% compared to placebo, with a reduction in HF hospitalizations of 20-40%. (1, 7-9)\n* GLP-1 receptor agonists have been shown to reduce the risk of MACE by 10-20% compared to placebo, with a reduction in HF hospitalizations of 30-50%. (1, 10-12)\n\nThe documents also highlight that both medication classes have additional benefits, such as weight loss and progression of kidney disease. (1, 7-9)\n\nIt is important to note that the recommendation for these medications is based on the available evidence from randomized controlled trials, and the cost-effectiveness of these treatments may vary depending on the specific patient population and healthcare setting. (18)",
      "ground_truth": "For patients with CCD who have type 2 diabetes, the use of either a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended to reduce the risk of MACE. These benefits are independent of their effects on glycemic control.",
      "context": "irrespective of diabetes status, is projected to be of uncertain value at US prices.30\n*Modi\ufb01ed from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.31\nSynopsis\nComprehensive cardiovascular risk reduction strategies\nare effective in patients with CCD and type 2 diabetes.32\nDespite these efforts, cardio vascular event rates remain\nhigh among patients with type 2 diabetes, even among\nwell-managed patients,\n1,10,33 and CAD remains the leading\ncause of morbidity and death. 34 Two...",
      "latency_seconds": 98.70264887809753,
      "token_count": 228.8,
      "throughput_tokens_per_sec": 2.3180735532496084,
      "cosine_similarity": 0.4520856110282282,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.2,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 176,
      "ground_truth_length_words": 48,
      "length_ratio": 3.6666666666666665,
      "has_hallucination": false
    },
    {
      "question_id": 4,
      "question": "In patients with CCD and angina, what are the recommended first-line anti-anginal therapies for symptom relief?",
      "answer": "Based on the provided medical documents, the recommended first-line anti-anginal therapies for symptom relief in patients with chronic coronary disease (CCD) and angina are beta blockers, non-dihydropyridine calcium channel blockers, and ivabradine. These therapies are recommended as they have been shown to decrease myocardial oxygen demand or increase arterial blood supply via vasodilatory actions, which can help relieve symptoms of angina.\n\nSpecifically, the 2012 ACC/AHA Multisociety Guideline for the Diagnosis and Management of Patients With SIHD recommends beta blockers as the first-line therapy for patients with CCD and normal left ventricular function. The guideline notes that beta blockers decrease myocardial oxygen demand by decreasing contractility, heart rate, or both, which can help relieve symptoms of angina.\n\nSimilarly, non-dihydropyridine calcium channel blockers are recommended as a first-line therapy for patients with CCD and normal left ventricular function. These medications decrease myocardial oxygen demand by decreasing calcium overload through inhibition of the late sodium current.\n\nIvabradine is also recommended as a first-line therapy for patients with CCD and normal left ventricular function. Ivabradine has been shown to decrease myocardial oxygen demand by decreasing heart rate, which can help relieve symptoms of angina.\n\nIt is important to note that the choice of anti-anginal therapy will depend on the individual patient's needs and medical history. The guideline recommends that patients with CCD and angina should be treated with the most appropriate therapy based on their individual clinical status, comorbidities, and other factors.\n\nIn summary, the recommended first-line anti-anginal therapies for symptom relief in patients with CCD and angina are beta blockers, non-dihydropyridine calcium channel blockers, and ivabradine. These medications have been shown to be effective in reducing symptoms of angina and improving quality of life for patients with CCD.",
      "ground_truth": "In patients with CCD and angina, anti-anginal therapy with either a beta blocker, calcium channel blocker (CCB), or long-acting nitrate is recommended for relief of angina or equivalent symptoms. Either a calcium channel blocker or beta blocker is recommended as first-line antianginal therapy.",
      "context": "with beta blockers, CCB, or long-acting nitrate therapies. *7,8\n1 B-NR\n4. In patients with CCD, sublingual nitroglycerin or nitroglycerin spray is recommended for immediate\nshort-term relief of angina or equivalent symptoms. *9,10\n3: Harm B-R\n5. In patients with CCD and normal LV function, the addition of ivabradine to standard anti-anginal therapy\nis potentially harmful. *11\n*Modi\ufb01ed from the 2012 ACC/AHA Multisociety Guideline for the Diagnosis and Management of Patients With SIHD.12\nSynopsis\n...",
      "latency_seconds": 126.09866952896118,
      "token_count": 370.5,
      "throughput_tokens_per_sec": 2.9381753303503886,
      "cosine_similarity": 0.3530778641437636,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.08333333333333333,
      "entity_overlap_truth": 0.2,
      "answer_length_words": 285,
      "ground_truth_length_words": 43,
      "length_ratio": 6.627906976744186,
      "has_hallucination": true
    },
    {
      "question_id": 5,
      "question": "What are the four medication classes that make up guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) according to the 2022 guidelines?",
      "answer": "Based on the provided medical documents, the four medication classes that make up guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) according to the 2022 guidelines are:\n\n1. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs): These medications are recommended as the first line of therapy for HFrEF, as they can improve cardiac function and reduce symptoms. According to the guidelines, ACE inhibitors or ARBs are recommended for all patients with HFrEF, regardless of their ejection fraction.\n2. Mineralocorticoid receptor antagonists (MRAs): These medications are recommended for patients with HFrEF who have a left ventricular ejection fraction (LVEF) of 40% or less. MRAs can help reduce symptoms and improve cardiac function in these patients.\n3. Beta blockers: These medications are recommended for all patients with HFrEF, regardless of their ejection fraction. Beta blockers can help reduce symptoms and improve cardiac function by slowing the heart rate and reducing the force of contractions.\n4. Sacubitril-valsartan: This medication is recommended as an alternative to ACE inhibitors or ARBs for patients with HFrEF who have a LVEF of 40% or less. Sacubitril-valsartan can help reduce symptoms and improve cardiac function in these patients.\n\nAccording to the guidelines, the choice of medication class and the intensity of therapy should be individualized based on patient factors such as age, comorbidities, and renal function. The guidelines also recommend that patients with HFrEF receive regular monitoring and follow-up to assess their response to treatment and make any necessary adjustments.",
      "ground_truth": "1. Sodium-glucose cotransporter-2 inhibitors (SGLT2i)\n2. Angiotensin receptor-neprilysin inhibitors (ARNi), angiotensin-converting enzyme inhibitors (ACEi), or angiotensin II receptor blockers (ARB)\n3. Beta blockers\n4. Mineralocorticoid receptor antagonists (MRA)",
      "context": "Titration of medical therapy for heart failure with\nreduced ejection fraction. J Am Coll Cardiol\n2019;73:2365/C0 83.\n23. Yancy CW, Januzzi Jr. JL, Allen LA, et al. 2017\nACC expert consensus decision pathway for optimi-\nzation of heart failure treatment: answers to 10 piv-\notal issues about heart failure with reduced ejection\nfraction: a report of the American College of Cardi-\nology Task Force on Expert Consensus Decision Path-\nways. J Am Coll Cardiol 2018;71:201/C0 30.\n24. Bhagat AA, Greene SJ,...",
      "latency_seconds": 107.93038773536682,
      "token_count": 321.1,
      "throughput_tokens_per_sec": 2.975065750595663,
      "cosine_similarity": 0.11712929409875962,
      "precision": 0.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.2,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 247,
      "ground_truth_length_words": 28,
      "length_ratio": 8.821428571428571,
      "has_hallucination": false
    },
    {
      "question_id": 6,
      "question": "How is heart failure with preserved ejection fraction (HFpEF) defined in terms of left ventricular ejection fraction (LVEF) percentage?",
      "answer": "Based on the provided medical documents, there is no specific definition of heart failure with preserved ejection fraction (HFpEF) in terms of left ventricular ejection fraction (LVEF) percentage. The documents provide some information on the diagnosis and classification of HFpEF, but do not provide a clear definition or threshold for LVEF percentage that distinguishes HFpEF from other types of heart failure.\n\nHowever, some studies have reported on the prevalence and characteristics of HFpEF based on LVEF percentage. For example, a study published in the Journal of Cardiac Failure found that among patients with heart failure and preserved ejection fraction (HFpEF), the majority had an LVEF percentage of 40% or higher [1]. Another study published in Circulation found that patients with HFpEF had an average LVEF percentage of 36% [2].\n\nIt is important to note that the definition and classification of HFpEF are still evolving, and there is ongoing debate among clinicians and researchers about the most appropriate way to diagnose and categorize this condition. Some experts have proposed using a combination of LVEF percentage, left ventricular volume, and other clinical variables to define HFpEF [3]. Others have suggested that HFpEF may be better defined as a syndrome characterized by specific clinical features, such as fatigue, shortness of breath, and swelling, regardless of LVEF percentage [4].\n\nIn summary, while there is some information available on the prevalence and characteristics of HFpEF based on LVEF percentage, there is no clear definition or threshold for HFpEF in terms of LVEF percentage provided in the medical documents. Further research and consensus are needed to clarify the diagnosis and classification of this condition.\n\nReferences:\n\n[1] Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:61/C0 73.\n\n[2] Wilcox JE, Fang JC, Margulies KB, et al. Heart failure with recovered left ventricular ejection fraction: JACC Scienti\ufb01c Expert Panel. J Am Coll Cardiol 2020;76:719/C0 34.\n\n[3] Bozkurt B, Coats AJS, Tsutsui H, et al. Universal de\ufb01nition and classi\ufb01cation of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal De\ufb01nition of Heart Failure. J Card Fail 2021;27:387/C0 413.\n\n[4] Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to heart failure with preserved ejection fraction in the treatment of preserved cardiac function heart failure trial. Circ Heart Fail 2018;11:e004457.",
      "ground_truth": "HFpEF is defined as LVEF \u00e2\u2030\u00a550% with evidence of spontaneous or provokable increased left ventricular filling pressures (e.g., elevated natriuretic peptide levels, noninvasive or invasive hemodynamic measurements).",
      "context": "of the H2F-PEF model in diagnosing patients with\nheart failure and preserved ejection fraction. Circu-\nlation 2019;139:2377/C0 2379.\n7. Selvaraj S, Myhre PL, Vaduganathan M, et al.\nApplication of diagnostic algorithms for heart fail-\nure with preserved ejection fraction to the commu-\nnity. JACC Heart Fail 2020;8:640/C0 53.\n8. Pieske B, Tschope C, de Boer RA, et al. How to\ndiagnose heart failure with preserved ejection frac-\ntion: the HFA-PEFF diagnostic algorithm: a consen-\nsus recommendation fr...",
      "latency_seconds": 173.62331867218018,
      "token_count": 546.0,
      "throughput_tokens_per_sec": 3.1447388759508033,
      "cosine_similarity": 0.17721328474717984,
      "precision": 0.2,
      "hallucination_entities": [
        "Heart failure"
      ],
      "hallucination_count": 1,
      "contradiction_count": 1,
      "entity_overlap_context": 0.5714285714285714,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 420,
      "ground_truth_length_words": 27,
      "length_ratio": 15.555555555555555,
      "has_hallucination": true
    },
    {
      "question_id": 7,
      "question": "What are the criteria for implantable cardioverter-defibrillator (ICD) therapy for primary prevention of sudden cardiac death in patients with heart failure?",
      "answer": "Based on the provided medical documents, the criteria for implantable cardioverter-defibrillator (ICD) therapy for primary prevention of sudden cardiac death in patients with heart failure are as follows:\n\n1. LVEF (Left Ventricular Ejection Fraction) <35% or LVESV (Left Ventricular End-Diastolic Volume) >60 ml/m2: These criteria indicate that the patient is at high risk of sudden cardiac death and may benefit from ICD therapy.\n2. NYHA (New York Heart Association) class III or IV symptoms: Patients with severe heart failure symptoms may be good candidates for ICD therapy to reduce the risk of sudden cardiac death.\n3. Presence of genetic arrhythmogenic cardiomyopathy with high-risk features of sudden death: In patients with a known genetic predisposition to arrhythmias, ICD implantation may be reasonable to decrease the risk of sudden death.\n4. Anticipated requirement for significant (>40%) ventricular pacing with cardiac resynchronization therapy (CRT): Patients who require CRT and have a high risk of sudden cardiac death may benefit from ICD implantation to reduce this risk.\n5. Sinus rhythm, non-LBBB pattern, QRS duration 120-149 ms, and NYHA class III or ambulatory class IV on GDMT: Patients with these criteria may also be good candidates for ICD therapy to reduce the risk of sudden cardiac death.\n\nStatistics from the documents:\n\n* Of the 16 patients who underwent ICD implantation for primary prevention of sudden cardiac death, 7 (43.75%) had LVEF <35% and 9 (56.25%) had NYHA class III or IV symptoms.\n* Of the 36 patients who were considered for ICD implantation but did not meet the criteria, 10 (27.74%) had LVEF <35%, and 26 (72.26%) had NYHA class III or IV symptoms.\n\nIt is important to note that these criteria are based on the medical documents provided and may not be applicable to all patients with heart failure. A thorough evaluation by a cardiologist or electrophysiologist should be conducted before making any decisions regarding ICD therapy.",
      "ground_truth": "ICD therapy is recommended for primary prevention in patients who are at least 40 days post-myocardial infarction with LVEF \u00e2\u2030\u00a430% and NYHA class I symptoms while receiving GDMT, and who have a reasonable expectation of meaningful survival for >1 year.",
      "context": "arrhythmia. Multicenter Automatic De \ufb01brillator\nImplantation Trial Investigators. N Engl J Med\n1996;335:1933/C0 40.\n5. Buxton AE, Lee KL, Fisher JD, et al. A random-\nized study of the prevention of sudden death in\npatients with coronary artery disease. Multicenter\nUnsustained Tachycardia Trial Investigators. N Engl J\nMed 1999;341:1882/C0 90.\n6. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic\nimplantation of a de\ufb01brillator in patients with myo-\ncardial infarction and reduced ejection fraction. N\n...",
      "latency_seconds": 137.43589901924133,
      "token_count": 406.90000000000003,
      "throughput_tokens_per_sec": 2.960652950966131,
      "cosine_similarity": 0.29917166916276056,
      "precision": 0.6666666666666666,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.4,
      "answer_length_words": 313,
      "ground_truth_length_words": 40,
      "length_ratio": 7.825,
      "has_hallucination": false
    },
    {
      "question_id": 8,
      "question": "What diagnostic biomarker tests are recommended for patients presenting with dyspnea to support or exclude a diagnosis of heart failure?",
      "answer": "Based on the provided medical documents, the following diagnostic biomarker tests are recommended for patients presenting with dyspnea to support or exclude a diagnosis of heart failure:\n\n1. B-type natriuretic peptide (BNP) and N-terminal probrain natriuretic peptide (NT-proBNP): These tests have been shown to provide incremental diagnostic value to clinical judgment when the cause of dyspnea is unclear and the physical examination equivocal. Measuring BNP and NT-proBNP levels in the ambulatory setting can help rule in or rule out heart failure (HF) (1/C0 9).\n2. Echocardiography: This test can help evaluate left ventricular function, which is essential for diagnosing HF (48/C0 75).\n3. Cardiopulmonary exercise testing (CPET): This test can provide information on exercise capacity and can help distinguish between respiratory vs cardiac etiologies of dyspnea (18/C0 64).\n4. Growth differentiation factor-15 (GDF-15): This biomarker has been shown to be associated with a greater risk for adverse short- and long-term outcomes in patients with HF, including all-cause and cardiovascular death (47/C0 20).\n\nStatistics:\n\n* A higher level of BNP and NT-proBNP is associated with a greater risk for adverse short- and long-term outcomes in patients with HF (47/C0 20).\n* In the emergency setting, BNP and NT-proBNP levels have higher sensitivity than specificity and may be more useful for ruling out HF than ruling in HF (50/C0 53).\n* A weighted score based on six predictive variables, including obesity, atrial fibrillation, age >60 years, treatment with two or more antihypertensive medications, echocardiographic E/e0 ratio >9, and echocardio-graphic PA systolic pressure >35 mm Hg, can help determine the likelihood of HFpEF (24/C0 7).\n\nIn summary, measuring BNP and NT-proBNP levels, performing echocardiography, and using CPET can help support or exclude a diagnosis of heart failure in patients presenting with dyspnea.",
      "ground_truth": "Measurement of B-type natriuretic peptide (BNP) or N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) is useful to support a diagnosis or exclusion of heart failure.",
      "context": "dard exercise testing variables, such as heart rate,\nblood pressure, electrocardiographic \ufb01ndings,\nand symptoms to provide insights into the physio-\nlogic mechanisms underlying a patient\u2019s dyspnea.\nIn particular, CPET can help to distinguish respira-\ntory vs cardiac etiologies of dyspnea. If exercise\ncapacity is diminished but cardiopulmonary\nresponses are normal, other causes of dyspnea,\nsuch as metabolic abnormalities and decondition-\ning, should be considered.\n4.8. Initial and Serial Evaluati...",
      "latency_seconds": 151.2430100440979,
      "token_count": 375.7,
      "throughput_tokens_per_sec": 2.484081742954317,
      "cosine_similarity": 0.25802604440592103,
      "precision": 0.75,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.5714285714285714,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 289,
      "ground_truth_length_words": 25,
      "length_ratio": 11.56,
      "has_hallucination": false
    },
    {
      "question_id": 9,
      "question": "What is the definition of hypertension according to office blood pressure measurements?",
      "answer": "According to the guidelines provided in the context, hypertension is defined as a systolic blood pressure (SBP) of 140 mmHg or higher, or a diastolic blood pressure (DBP) of 90 mmHg or higher, measured in a standardized office setting using validated auscultatory or semi-automatic devices. The guidelines also provide that the diagnosis of hypertension should be confirmed by repeated office BP measurements over a number of visits, or by 24-hour ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM).",
      "ground_truth": "According to Table 12, hypertension is defined as office blood pressure \u00e2\u2030\u00a5140 mmHg systolic and/or \u00e2\u2030\u00a590 mmHg diastolic.",
      "context": ".............................................\n.........................\n4.7.1. Definition and classification of hypertension\nBP is classified according to seated office BP (Table 12), with approxi-\nmately corresponding values according to ABPM or home BP average\nvalues inTable 13.\n4.7.2. Blood pressure measurement\n4.7.2.1 Office blood pressure measurement\nOffice BP should be measured in standardized conditions using\nvalidated auscultatory or (semi)automatic devices, as described in\nTable 14.\n4.7...",
      "latency_seconds": 64.83955883979797,
      "token_count": 105.3,
      "throughput_tokens_per_sec": 1.624008581862339,
      "cosine_similarity": 0.3969337161819286,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.13333333333333333,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 81,
      "ground_truth_length_words": 18,
      "length_ratio": 4.5,
      "has_hallucination": false
    },
    {
      "question_id": 10,
      "question": "What are the recommended LDL-C (low-density lipoprotein cholesterol) goals for patients with established atherosclerotic cardiovascular disease (ASCVD)?",
      "answer": "Based on the provided medical documents, the recommended LDL-C goals for patients with established ASCVD are as follows:\n\nFor patients with a history of cardiovascular events (such as myocardial infarction or stroke) within the past 2 years, an even lower LDL-C goal of <1.0 mmol/L (40 mg/dL) may be considered.\n\nFor patients with ASCVD who experience a second vascular event within 2 years while taking maximum tolerated statin-based therapy, an LDL-C goal of <1.8 mmol/L (70 mg/dL) may be considered.\n\nThe stepwise approach to treatment goals for ASCVD patients is as follows:\n\n* STEP 1: Achieve an LDL-C level of <5% or a reduction of \u226510% from the patient's baseline level.\n* STEP 2: Consider risk modifiers, lifetime CVD risk, patient preferences, and treatment benefits and side effects.\n\nIt is important to note that these goals are based on the available evidence from clinical trials and observational studies, and may be subject to change as new research emerges.",
      "ground_truth": "In patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a \u00e2\u2030\u00a550% reduction of LDL-C vs. baseline is recommended.",
      "context": "o fn o n - H D L - Ca sat r e a t m e n tt a r g e ta si tc a p t u r e st h ei n f o r m a t i o n\nregarding all apolipoprotein-B-containing lipoproteins.\n513 We suggest\nit as a reasonable alternative treatment goal for all patients, particularly\nfor those with hypertriglyceridaemia or DM. How non-HDL-C levels\ncorrespond to commonly used LDL-C goals is shown inTable10.\n4.6.1.4 Apolipoprotein B\nApolipoprotein B provides a direct estimate of the total concentra-\ntion of atherogenic lipid particle...",
      "latency_seconds": 89.36842942237854,
      "token_count": 205.4,
      "throughput_tokens_per_sec": 2.298350785927164,
      "cosine_similarity": 0.36396520348127653,
      "precision": 0.1111111111111111,
      "hallucination_entities": [
        "myocardial infarction",
        "1.8 mmol/L"
      ],
      "hallucination_count": 2,
      "contradiction_count": 0,
      "entity_overlap_context": 0.4117647058823529,
      "entity_overlap_truth": 0.3333333333333333,
      "answer_length_words": 158,
      "ground_truth_length_words": 27,
      "length_ratio": 5.851851851851852,
      "has_hallucination": true
    },
    {
      "question_id": 11,
      "question": "What is the recommended physical activity for adults to reduce all-cause mortality, CV mortality, and morbidity?",
      "answer": "Based on the provided medical documents, the recommended physical activity for adults to reduce all-cause mortality, CV mortality, and morbidity is as follows:\n\n1. Aerobic exercise: Engage in at least 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity aerobic PA per week, or an equivalent combination thereof. This can be achieved through activities such as brisk walking, jogging, cycling, or swimming.\n2. Resistance exercise: Perform resistance exercises at least 2 days per week in addition to aerobic activity. Examples of resistance exercises include weightlifting, bodyweight exercises, or using resistance bands.\n3. Nutrition and alcohol consumption: Adopt a healthy diet rich in fruits, vegetables, whole grains, and lean protein sources, and restrict salt intake. Limit alcohol consumption to a maximum of 100 grams per week.\n4. Sedentary behavior: Reduce sedentary time by engaging in light physical activity throughout the day, such as stretching or taking a short walk.\n5. Dose-response relationship: Engage in physical activity at higher doses (e.g., frequency, duration, and intensity) to achieve greater health benefits.\n6. Mechanisms of benefit: Exercise has anti-atherosclerotic, antiarrhythmic, antithrombotic, anti-ischemic, and antidepressant effects, which contribute to improved outcomes in individuals with CVD.\n7. Contraindications: Exercise is contraindicated in patients with severe, life-threatening, and unstable conditions, such as unstable angina or other high-grade arrhythmias.\n\nRelevant statistics and findings from the provided documents include:\n\n* Engaging in 150-300 minutes of moderate-intensity aerobic PA per week can reduce all-cause mortality by 22% (Hupin et al., 2015).\n* Performing resistance exercises in addition to aerobic activity can reduce CV mortality by 25% (Patterson et al., 2019).\n* Reducing sedentary behavior can lower BP and risk of CVD (Sattelmair et al., 2011).\n* Adopting a Mediterranean-like diet can lower the risk of CVD (Hillman et al., 2018).\n* Limiting alcohol consumption to a maximum of 100 grams per week can reduce the risk of CVD (Ekelund et al., 2019).",
      "ground_truth": "It is recommended for adults of all ages to strive for at least 150\u00e2\u20ac\u201c300 min a week of moderate-intensity or 75\u00e2\u20ac\u201c150 min a week of vigorous-intensity aerobic physical activity, or an equivalent combination thereof.",
      "context": "It is recommended for adults of all ages to strive\nfor at least 150 - 300 min a week of moderate-\nintensity or 75 - 150 min a week of vigorous-\nintensity aerobic PA, or an equivalent combina-\ntion thereof, to reduce all-cause mortality, CV\nmortality, and morbidity.\n371,372\nIA\nIt is recommended that adults who cannot per-\nform 150 min of moderate-intensity PA a week\nshould stay as active as their abilities and health\ncondition allow.\n373,374\nIB\nIt is recommended to reduce sedentary time to\nengage...",
      "latency_seconds": 164.89519715309143,
      "token_count": 405.6,
      "throughput_tokens_per_sec": 2.459744170859229,
      "cosine_similarity": 0.32877388325245066,
      "precision": 0,
      "hallucination_entities": [
        "2 days"
      ],
      "hallucination_count": 1,
      "contradiction_count": 2,
      "entity_overlap_context": 0.2,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 312,
      "ground_truth_length_words": 34,
      "length_ratio": 9.176470588235293,
      "has_hallucination": true
    },
    {
      "question_id": 12,
      "question": "What is the recommended maximum alcohol consumption per week for cardiovascular disease prevention?",
      "answer": "Based on the provided medical documents, the recommended maximum alcohol consumption per week for cardiovascular disease prevention is 100 grams per week. This is stated in the document as \"It is recommended to restrict alcohol consumption to a maximum of 100 g per week.\" (IB)",
      "ground_truth": "It is recommended to restrict alcohol consumption to a maximum of 100 g per week.",
      "context": "108). \nI A \n6. Adult men and women with elevated BP or hypertension who currently \nconsume alcohol should be advised to drink no more than 2 and 1 standard \ndrinks* per day, respectively (109-114). \nI \nSBP:   \nA \n7. Use of BP-lowering medications is recommended for secondary prevention \nof recurrent CVD events in patients with clinical CVD and an average SBP of \n130 mm Hg or higher or  an average DBP of 80 mm Hg or higher, and  for \nprimary prevention in adults with an estimated 10 -year atheros...",
      "latency_seconds": 48.30694246292114,
      "token_count": 58.5,
      "throughput_tokens_per_sec": 1.2110060587026952,
      "cosine_similarity": 0.6602410368662078,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.0,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 45,
      "ground_truth_length_words": 15,
      "length_ratio": 3.0,
      "has_hallucination": false
    },
    {
      "question_id": 13,
      "question": "According to the 2020 ACC/AHA guidelines, what are the stages of valvular heart disease and their definitions?",
      "answer": "Based on the provided medical documents, the stages of valvular heart disease and their definitions are as follows:\n\nStage A: Mild symptoms (e.g., fatigue, shortness of breath) with no significant left ventricular dysfunction or pulmonary artery hypertension.\n\n* Definition: Patients with mild symptoms but no significant left ventricular dysfunction or pulmonary artery hypertension.\n* Statistics: Approximately 25% of patients with valvular heart disease are in Stage A (1).\n\nStage B: Moderate symptoms (e.g., shortness of breath, fatigue) with mild left ventricular dysfunction or pulmonary artery hypertension.\n\n* Definition: Patients with moderate symptoms and mild left ventricular dysfunction or pulmonary artery hypertension.\n* Statistics: Approximately 50% of patients with valvular heart disease are in Stage B (1).\n\nStage C: Severe symptoms (e.g., shortness of breath, fatigue) with significant left ventricular dysfunction or pulmonary artery hypertension.\n\n* Definition: Patients with severe symptoms and significant left ventricular dysfunction or pulmonary artery hypertension.\n* Statistics: Approximately 25% of patients with valvular heart disease are in Stage C (1).\n\nStage D: End-stage heart failure with symptoms of heart failure, such as shortness of breath, fatigue, and swelling in the legs and ankles.\n\n* Definition: Patients with end-stage heart failure with symptoms of heart failure.\n* Statistics: Approximately 10% of patients with valvular heart disease are in Stage D (1).\n\nIt is important to note that these stages are based on the severity of symptoms and the degree of left ventricular dysfunction or pulmonary artery hypertension, and may not always reflect the underlying pathology of the valve disease. The 2020 ACC/AHA guidelines provide more detailed information on the classification and definition of each stage (1).",
      "ground_truth": "- Stage A (At risk): Patients with risk factors for developing VHD\n- Stage B (Progressive): Patients with progressive VHD (mild to moderate severity and asymptomatic)\n- Stage C (Asymptomatic severe): Asymptomatic patients who meet criteria for severe VHD\n  + C1: Asymptomatic patients with severe VHD in whom the LV or RV remains compensated\n  + C2: Asymptomatic patients with severe VHD with decompensation of LV or RV\n- Stage D (Symptomatic severe): Patients who have developed symptoms as a result of VHD",
      "context": "Top 10 Take Home Messages \n1. Disease stages in patients with valvular heart \ndise\nase should be classified (Stages A, B, C, \nand D) on the basis of symptoms, valve \nanatomy, the severity of valve dysfunction, \nand the response of the ventricle and \npulmonary circulation.\n6\n\nTop 10 Take Home Messages \n2. In the evaluation of a patient with valvular heart disease, history and \nphysical examination findings should be correlated with the results of \nnoninvasive testing (i.e., ECG, chest x-ray, tran...",
      "latency_seconds": 114.85169911384583,
      "token_count": 349.7,
      "throughput_tokens_per_sec": 3.044796051762044,
      "cosine_similarity": 0.29911574244667666,
      "precision": 0.0,
      "hallucination_entities": [
        "heart failure",
        "hypertension"
      ],
      "hallucination_count": 2,
      "contradiction_count": 0,
      "entity_overlap_context": 0.0,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 269,
      "ground_truth_length_words": 82,
      "length_ratio": 3.2804878048780486,
      "has_hallucination": true
    },
    {
      "question_id": 14,
      "question": "In patients with atrial fibrillation and valvular heart disease, what is the recommended anticoagulation for those with rheumatic mitral stenosis or a mechanical prosthesis?",
      "answer": "Based on the provided medical documents, for patients with rheumatic mitral stenosis or a mechanical prosthesis and atrial fibrillation, long-term anticoagulation with a vitamin K antagonist (VKA) is recommended. This is stated in recommendation 3 of the \"Anticoagulation for AF in Patients With VHD\" section, which states: \"For patients with rheumatic mitral stenosis or a mechanical prosthesis and atrial fibrillation, long-term anticoagulation with a vitamin K antagonist is recommended.\"\n\nThe document provides further support for this recommendation by stating that patients with rheumatic mitral stenosis or a mechanical prosthesis and atrial fibrillation should have oral anticoagulation with a VKA. This is stated in recommendation 1 of the \"Anticoagulation for AF in Patients With VHD\" section, which states: \"Patients with rheumatic mitral stenosis or a mechanical prosthesis and atrial fibrillation should have oral anticoagulation with a vitamin K antagonist.\"\n\nThere are no statistics or findings provided in the document that contradict this recommendation. In fact, the document emphasizes the importance of long-term anticoagulation for patients with rheumatic mitral stenosis or a mechanical prosthesis and atrial fibrillation to prevent thromboembolic events.\n\nTherefore, based on the provided medical documents, the recommended anticoagulation for patients with rheumatic mitral stenosis or a mechanical prosthesis and atrial fibrillation is long-term anticoagulation with a VKA.",
      "ground_truth": "Oral anticoagulation with a vitamin K antagonist is recommended.",
      "context": "Antithrombotic Therapy for Prosthetic Valves\nCOR LOE Recommendations\n1 A\n1. In patients with a mechanical prosthetic valve, anticoagulation with a VKA is\nrecommended.\n1 B-NR\n2. For patients with a mechanical bileaflet or current-generation single-tilting disk AV R\nand no risk factors for thromboembolism, anticoagulation with a VKA to achieve an\nINR of 2.5 is recommended.\n1 B-NR\n3. For patients with a mechanical AV Rand additional risk factors for thromboembolism\n(e.g., AF, previous thromboemboli...",
      "latency_seconds": 82.065114736557,
      "token_count": 270.40000000000003,
      "throughput_tokens_per_sec": 3.2949445189716737,
      "cosine_similarity": 0.3419877151235818,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 208,
      "ground_truth_length_words": 9,
      "length_ratio": 23.11111111111111,
      "has_hallucination": false
    },
    {
      "question_id": 15,
      "question": "According to the guidelines, what are the indications for transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR)?",
      "answer": "According to the guidelines provided, the indications for transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) are as follows:\n\nIndications for TAVI:\n\n* Expanding indications based on multiple randomized trials of TAVI versus SAVR\n* Patients with severe aortic stenosis who meet criteria for AVR\n* Selection of type of intervention based on shared decision-making process considering lifetime risks and benefits of type of valve (mechanical versus bioprosthetic) and type of approach (transcatheter versus surgical)\n\nIndications for SAVR:\n\n* Patients with symptomatic, severe aortic stenosis who meet criteria for AVR\n* Selection of type of intervention based on shared decision-making process considering patient-specific procedural risks, values, trade-offs, and preferences\n\nRelevant statistics or findings from the guidelines include:\n\n* TAVI is associated with lower mortality rates compared to SAVR at 1 year (6.5% vs 8.5%) and 2 years (10.5% vs 14.5%) after intervention (Source: COR LOE Recommendations, Section 9)\n* TAVI is associated with lower rates of new-onset atrial fibrillation compared to SAVR at 1 year (3.2% vs 6.7%) and 2 years (4.5% vs 8.5%) after intervention (Source: COR LOE Recommendations, Section 9)\n* TAVI is associated with lower rates of major adverse cardiovascular events (MACE) compared to SAVR at 1 year (12.3% vs 18.5%) and 2 years (17.5% vs 24.5%) after intervention (Source: COR LOE Recommendations, Section 9)\n\nIn summary, TAVI is recommended for patients with severe aortic stenosis who meet criteria for AVR and are suitable candidates for transcatheter intervention, while SAVR is recommended for patients who require AVR but are not suitable candidates for TAVI due to various factors such as age, comorbidities, or other clinical considerations.",
      "ground_truth": "- For patients <65 years or life expectancy >20 years: SAVR recommended\n- For patients 65-80 years: Either SAVR or transfemoral TAVI after shared decision-making\n- For patients >80 years or life expectancy <10 years: Transfemoral TAVI recommended in preference to SAVR\n- For high/prohibitive surgical risk: TAVI recommended if predicted survival >12 months",
      "context": "Top 10 Take Home Messages \n6. Indications for transcatheter aortic valve implantation are \nexpanding as a result of multiple randomized trials of \ntranscatheter aortic valve implantation atrio versus surgical \naortic valve replacement.  The choice of type of intervention for \na patient with severe aortic stenosis should be a shared decision-\nmaking process that considers the lifetime risks and benefits \nassociated with type of valve (mechanical versus bioprosthetic) \nand type of approach (transc...",
      "latency_seconds": 101.7965087890625,
      "token_count": 353.6,
      "throughput_tokens_per_sec": 3.4735965329882954,
      "cosine_similarity": 0.287064365781795,
      "precision": 0.5,
      "hallucination_entities": [
        "2 years",
        "1 year"
      ],
      "hallucination_count": 2,
      "contradiction_count": 0,
      "entity_overlap_context": 0.0,
      "entity_overlap_truth": 0.2857142857142857,
      "answer_length_words": 272,
      "ground_truth_length_words": 54,
      "length_ratio": 5.037037037037037,
      "has_hallucination": true
    },
    {
      "question_id": 16,
      "question": "What is the recommended management for asymptomatic patients with chronic severe aortic regurgitation and normal LV systolic function (Stage C1)?",
      "answer": "Based on the provided medical documents, there is no specific recommendation for the management of asymptomatic patients with chronic severe aortic regurgitation and normal LV systolic function (Stage C1). The documents do not provide any guidance on the appropriate course of action for these patients.\n\nThe closest recommendation can be found in the section on Timing of Intervention for Patients with Chronic AR, which states that in asymptomatic patients with severe AR and normal LV systolic function (Stage C1), aortic valve surgery may be considered when there is a progressive decline in LVEF on at least 3 serial studies to the low-normal range (LVEF 55% to 60%) or a progressive increase in LV dilation into the severe range (LV end-diastolic dimension [LVEDD] >65 mm). However, this recommendation is not specific to patients with chronic severe aortic regurgitation.\n\nTherefore, based on the provided medical documents, I don't have specific information about the recommended management for asymptomatic patients with chronic severe aortic regurgitation and normal LV systolic function (Stage C1).",
      "ground_truth": "- Aortic valve surgery is indicated if undergoing cardiac surgery for other indications\n- In patients with low surgical risk, surgery may be considered with progressive decline in LVEF to 55-60% on \u00e2\u2030\u00a53 studies or progressive LV dilation (LVEDD >65 mm)",
      "context": "Timing of Intervention for Patients with Chronic AR\nCOR LOE Recommendations\n1 B-NR 1. In symptomatic patients with severe AR (Stage D), aortic valve surgery\nis indicated regardless of LV systolic function.\n1 B-NR\n2. In asymptomatic patients with chronic severe AR and LV systolic\ndysfunction (LVEF \u226455%) (Stage C2), aortic valve surgery is indicated\nif no other cause for systolic dysfunction is identified.\n1 C-EO 3. In patients with severe AR (Stage C or D) who are undergoing cardiac\nsurgery for o...",
      "latency_seconds": 58.254467248916626,
      "token_count": 218.4,
      "throughput_tokens_per_sec": 3.7490687034660275,
      "cosine_similarity": 0.32376334974148935,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.5,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 168,
      "ground_truth_length_words": 41,
      "length_ratio": 4.097560975609756,
      "has_hallucination": false
    },
    {
      "question_id": 17,
      "question": "For an adult patient with hypertension and chronic kidney disease, what blood pressure treatment goal is recommended in the 2017 ACC/AHA guideline, as adapted in the 2019 document?",
      "answer": "Based on the provided medical documents, the recommended blood pressure treatment goal for an adult patient with hypertension and chronic kidney disease is less than 130/80 mm Hg. This is adapted from recommendation 7 in the 2017 ACC/AHA guideline, which states that adults with hypertension and chronic kidney disease should be treated to a BP goal of less than 130/80 mm Hg (128-133).",
      "ground_truth": "Treatment to a BP goal of less than 130/80 mm Hg is recommended.",
      "context": "18 \n \nI \nSBP:  \nB-RSR \n4. In adults with hypertension and chronic kidney disease, treatment to a BP goal of \nless than 130/80 mm Hg is recommended (128-133).  \n \nAdapted from recommendations in the 2017 \nACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the \nPrevention, Detection, Evaluation, and Management of High Blood Pressure in Adults \n(12). \nDBP:  \nC-EO \nI \nSBP:  \nB-RSR \n5. In adults with T2DM and hypertension, antihypertensive drug treatment should be \ninitiated at a BP of 13...",
      "latency_seconds": 54.262508392333984,
      "token_count": 81.9,
      "throughput_tokens_per_sec": 1.5093294141110982,
      "cosine_similarity": 0.46121912962129324,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 63,
      "ground_truth_length_words": 13,
      "length_ratio": 4.846153846153846,
      "has_hallucination": false
    },
    {
      "question_id": 18,
      "question": "For primary prevention in a 40-75 year old adult with diabetes mellitus, what intensity of statin therapy is recommended by the 2018 Cholesterol Guideline, regardless of their estimated 10-year ASCVD risk?",
      "answer": "Based on the provided medical documents, the 2018 Cholesterol Guideline recommends moderate-intensity statin therapy for intermediate-risk adults with diabetes mellitus, regardless of their estimated 10-year ASCVD risk. The guideline defines intermediate-risk individuals as those with a 10-year ASCVD risk between 5% and 20%.\n\nAccording to the guideline, in intermediate-risk patients, LDL -C levels should be reduced by 30% or more, and for optimal ASCVD risk reduction, especially in high-risk patients, levels should be reduced by 50% or more. However, the guideline does not provide specific intensity of statin therapy recommendations based on estimated 10-year ASCVD risk.\n\nThe guideline mentions that clinicians and patients should engage in a risk discussion that considers risk factors, such as age, sex, race, and comorbidities, to determine the appropriate intensity of statin therapy. The guideline also suggests that other preventive treatments, such as dual antithrombotic pathway inhibition or anti-inflammatory therapy with colchicine, may be considered for adults with type 2 diabetes mellitus.\n\nOverall, while the guideline does not provide specific intensity of statin therapy recommendations based on estimated 10-year ASCVD risk, it emphasizes the importance of a risk-based approach to determine the appropriate treatment for primary prevention in adults with diabetes mellitus.",
      "ground_truth": "Moderate-intensity statin therapy is indicated.",
      "context": "or more (148, 151-156). \nAdapted from recommendations in the 2018 \nAHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the \nManagement of Blood Cholesterol (9). \nI A \n3. In adults 40 to 75 years of age with diabetes, regardless of estimated 10-year ASCVD \nrisk, moderate-intensity statin therapy is indicated (157-165).  \nIncluded from recommendations in the 2018 \nAHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the \nManagement of Blood Cholesterol (9). \nI B-R ...",
      "latency_seconds": 109.79613637924194,
      "token_count": 256.1,
      "throughput_tokens_per_sec": 2.332504662235258,
      "cosine_similarity": 0.13027336210834875,
      "precision": 0.5,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.1,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 197,
      "ground_truth_length_words": 5,
      "length_ratio": 39.4,
      "has_hallucination": false
    }
  ],
  "mistral:latest": [
    {
      "question_id": 1,
      "question": "What is the recommended first-line therapy for lipid lowering in patients with chronic coronary disease (CCD), and what is the target LDL-C reduction?",
      "answer": " Based on the provided medical documents, for patients with chronic coronary disease (CCD), the recommended first-line therapy for lipid lowering is a high-intensity statin. The target LDL-C reduction in these patients is more than 50% from baseline levels. This recommendation is supported by multiple clinical trials that have established the effectiveness and safety of high-intensity statin therapy in reducing LDL-C levels and cardiovascular morbidity and mortality rates (as mentioned in sections 1-3). However, it's important to note that individual responses can vary substantially, and monitoring the effect on LDL-C levels is recommended, with assessment of LDL-C levels 4 - 6 weeks after any treatment strategy initiation or change (as stated in the context). Additionally, if additional LDL-C lowering is necessary in patients on maximally tolerated statin therapy, clinicians should prioritize use of ezetimibe and PCSK9 monoclonal antibodies unless not tolerated or effective in achieving desired LDL-C levels (as mentioned in section 14-17).",
      "ground_truth": "Statins remain first-line therapy for lipid lowering in patients with CCD. The aim with high-intensity statin therapy is to achieve a \u00e2\u2030\u00a550% reduction in LDL-C levels to reduce the risk of major adverse cardiovascular events (MACE). For patients in whom high-intensity statin therapy is contraindicated or not tolerated, moderate-intensity statin therapy is recommended with the aim of achieving a 30% to 49% reduction in LDL-C levels.",
      "context": "The expected LDL-C reductions in response to therapy are\nshown in Figure 13, and may vary widely among individuals.\nTherefore, monitoring the effect on LDL-C levels is recommended,\nwith assessment of LDL-C levels 4 - 6 weeks after any treatment\nstrategy initiation or change.\nTreatment Average LDL-C reduction\nIntensity of lipid-lowering treatment\nModerate-intensity statin\nHigh-intensity statin\nHigh-intensity statin plus ezetimibe\nPCSK9 inhibitor\nPCSK9 inhibitor plus high-intensity statin\nPCSK9 in...",
      "latency_seconds": 102.2442638874054,
      "token_count": 197.6,
      "throughput_tokens_per_sec": 1.9326267556447307,
      "cosine_similarity": 0.5602762212289814,
      "precision": 0.6666666666666666,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.17647058823529413,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 152,
      "ground_truth_length_words": 66,
      "length_ratio": 2.303030303030303,
      "has_hallucination": false
    },
    {
      "question_id": 2,
      "question": "When is long-term beta-blocker therapy NOT recommended for improving outcomes in patients with chronic coronary disease?",
      "answer": " Based on the provided medical documents, long-term beta-blocker therapy is not recommended for improving outcomes in patients with chronic coronary disease (CCD) without previous myocardial infarction (MI) or left ventricular ejection fraction (LVEF) less than 50%. This conclusion is derived from the findings of multiple studies, including the REACH registry and a post hoc analysis from the CHARISMA trial. In these studies, the use of beta-blocker therapy did not show significant benefits in reducing major adverse cardiovascular events (MACE) among CCD patients without a history of MI. However, it's important to note that if there are other primary indications for beta-blocker therapy such as angina, uncontrolled hypertension, or arrhythmias, their use may still be considered based on a comprehensive screening and assessment of the patient's symptoms and comorbid conditions.",
      "ground_truth": "Long-term beta-blocker therapy is not recommended to improve outcomes in patients with CCD in the absence of myocardial infarction in the past year, left ventricular ejection fraction \u00e2\u2030\u00a450%, or another primary indication for beta-blocker therapy (such as angina, uncontrolled hypertension, or arrhythmias).",
      "context": "era. Other primary indications for beta blockers may\ninclude their use for angina, uncontrolled hypertension,\nor arrhythmias. A comprehensive screening as well as\nassessment of their symptoms and comorbid conditions\nis recommended given that beta-blocker therapy may still\nbe indicated for its antianginal properties (see Section\n4.3.6 ), antihypertensive properties (see Section 4.2.7 ,\n\u201cBlood Pressure Management \u201d), or for its negative chro-\nnotropic effects among patients with rhythm disturbance...",
      "latency_seconds": 56.09669065475464,
      "token_count": 167.70000000000002,
      "throughput_tokens_per_sec": 2.989481162660816,
      "cosine_similarity": 0.5251144814892539,
      "precision": 0.8,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.38461538461538464,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 129,
      "ground_truth_length_words": 42,
      "length_ratio": 3.0714285714285716,
      "has_hallucination": true
    },
    {
      "question_id": 3,
      "question": "For patients with CCD and type 2 diabetes, what two classes of glucose-lowering medications are recommended to reduce cardiovascular risk?",
      "answer": " Based on the provided medical documents, for patients with CCD (Chronic Coronary Disease) and type 2 diabetes, two classes of glucose-lowering medications are recommended to reduce cardiovascular risk. These are SGLT2 inhibitors and GLP-1 receptor agonists. Both medications have been shown to significantly reduce the risk of Major Adverse Cardiovascular Events (MACE), with additional benefits in terms of weight loss and progression of kidney disease.\n\nFor instance, SGLT2 inhibitors are particularly effective in reducing incident and worsening Heart Failure (HF) for patients at risk, while GLP-1 receptor agonists primarily reduce the risk of atherosclerotic events such as Myocardial Infarction (MI) and stroke. However, it's important to note that there is no compelling evidence available that either medication reduces cardiovascular risk in patients with CCD but without type 2 diabetes.\n\nThe benefits of these medications are supported by various studies, including the EMPA-REG OUTCOME(R) trial for SGLT2 inhibitors and the Liraglutide and cardiovascular outcomes in type 2 diabetes study for GLP-1 receptor agonists.",
      "ground_truth": "For patients with CCD who have type 2 diabetes, the use of either a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended to reduce the risk of MACE. These benefits are independent of their effects on glycemic control.",
      "context": "irrespective of diabetes status, is projected to be of uncertain value at US prices.30\n*Modi\ufb01ed from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.31\nSynopsis\nComprehensive cardiovascular risk reduction strategies\nare effective in patients with CCD and type 2 diabetes.32\nDespite these efforts, cardio vascular event rates remain\nhigh among patients with type 2 diabetes, even among\nwell-managed patients,\n1,10,33 and CAD remains the leading\ncause of morbidity and death. 34 Two...",
      "latency_seconds": 67.74444222450256,
      "token_count": 210.6,
      "throughput_tokens_per_sec": 3.108742106135872,
      "cosine_similarity": 0.44055961280948014,
      "precision": 0.4,
      "hallucination_entities": [
        "Myocardial Infarction"
      ],
      "hallucination_count": 1,
      "contradiction_count": 0,
      "entity_overlap_context": 0.4,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 162,
      "ground_truth_length_words": 48,
      "length_ratio": 3.375,
      "has_hallucination": true
    },
    {
      "question_id": 4,
      "question": "In patients with CCD and angina, what are the recommended first-line anti-anginal therapies for symptom relief?",
      "answer": " Based on the provided medical documents, the recommended first-line anti-anginal therapies for symptom relief in patients with CCD and angina are beta blockers. This recommendation is not strongly based on early randomized, placebo-controlled studies but has been considered the first to use due to their effectiveness in relieving symptoms. However, it's important to note that full freedom from angina is only achieved in 40% to 50% of patients, depending on anginal frequency at the onset of treatment.",
      "ground_truth": "In patients with CCD and angina, anti-anginal therapy with either a beta blocker, calcium channel blocker (CCB), or long-acting nitrate is recommended for relief of angina or equivalent symptoms. Either a calcium channel blocker or beta blocker is recommended as first-line antianginal therapy.",
      "context": "with beta blockers, CCB, or long-acting nitrate therapies. *7,8\n1 B-NR\n4. In patients with CCD, sublingual nitroglycerin or nitroglycerin spray is recommended for immediate\nshort-term relief of angina or equivalent symptoms. *9,10\n3: Harm B-R\n5. In patients with CCD and normal LV function, the addition of ivabradine to standard anti-anginal therapy\nis potentially harmful. *11\n*Modi\ufb01ed from the 2012 ACC/AHA Multisociety Guideline for the Diagnosis and Management of Patients With SIHD.12\nSynopsis\n...",
      "latency_seconds": 40.75252962112427,
      "token_count": 100.10000000000001,
      "throughput_tokens_per_sec": 2.4562892397264267,
      "cosine_similarity": 0.19386143767500236,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.08333333333333333,
      "entity_overlap_truth": 0.2,
      "answer_length_words": 77,
      "ground_truth_length_words": 43,
      "length_ratio": 1.7906976744186047,
      "has_hallucination": false
    },
    {
      "question_id": 5,
      "question": "What are the four medication classes that make up guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) according to the 2022 guidelines?",
      "answer": " Based on the provided medical documents, the four medication classes that make up guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) according to the 2022 guidelines are:\n\n1. Angiotensin-converting enzyme inhibitors (ACE-inhibitors) or angiotensin receptor blockers (ARBs).\n2. Beta blockers.\n3. Mineralocorticoid receptor antagonists (MRAs), such as spironolactone or eplerenone.\n4. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), such as empagliflozin, dapagliflozin, or canagliflozin.",
      "ground_truth": "1. Sodium-glucose cotransporter-2 inhibitors (SGLT2i)\n2. Angiotensin receptor-neprilysin inhibitors (ARNi), angiotensin-converting enzyme inhibitors (ACEi), or angiotensin II receptor blockers (ARB)\n3. Beta blockers\n4. Mineralocorticoid receptor antagonists (MRA)",
      "context": "Titration of medical therapy for heart failure with\nreduced ejection fraction. J Am Coll Cardiol\n2019;73:2365/C0 83.\n23. Yancy CW, Januzzi Jr. JL, Allen LA, et al. 2017\nACC expert consensus decision pathway for optimi-\nzation of heart failure treatment: answers to 10 piv-\notal issues about heart failure with reduced ejection\nfraction: a report of the American College of Cardi-\nology Task Force on Expert Consensus Decision Path-\nways. J Am Coll Cardiol 2018;71:201/C0 30.\n24. Bhagat AA, Greene SJ,...",
      "latency_seconds": 47.86507201194763,
      "token_count": 85.8,
      "throughput_tokens_per_sec": 1.792538826194253,
      "cosine_similarity": 0.4160813444113253,
      "precision": 0.5,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.2,
      "entity_overlap_truth": 0.2,
      "answer_length_words": 66,
      "ground_truth_length_words": 28,
      "length_ratio": 2.357142857142857,
      "has_hallucination": false
    },
    {
      "question_id": 6,
      "question": "How is heart failure with preserved ejection fraction (HFpEF) defined in terms of left ventricular ejection fraction (LVEF) percentage?",
      "answer": " Based on the provided medical documents, heart failure with preserved ejection fraction (HFpEF) is defined as having a left ventricular ejection fraction (LVEF) of 50% or higher. This definition is consistent across multiple sources, such as the Heart Failure Society of America, the European Society of Cardiology, and the Japanese Heart Failure Society. For example, in the document \"Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021;27:387/C0 413.\", it is stated that HFpEF is defined as \"heart failure with a preserved ejection fraction (LVEF \u226550%)\". However, the documents do not provide specific statistics or findings related to the prevalence of HFpEF in terms of LVEF percentage.",
      "ground_truth": "HFpEF is defined as LVEF \u00e2\u2030\u00a550% with evidence of spontaneous or provokable increased left ventricular filling pressures (e.g., elevated natriuretic peptide levels, noninvasive or invasive hemodynamic measurements).",
      "context": "of the H2F-PEF model in diagnosing patients with\nheart failure and preserved ejection fraction. Circu-\nlation 2019;139:2377/C0 2379.\n7. Selvaraj S, Myhre PL, Vaduganathan M, et al.\nApplication of diagnostic algorithms for heart fail-\nure with preserved ejection fraction to the commu-\nnity. JACC Heart Fail 2020;8:640/C0 53.\n8. Pieske B, Tschope C, de Boer RA, et al. How to\ndiagnose heart failure with preserved ejection frac-\ntion: the HFA-PEFF diagnostic algorithm: a consen-\nsus recommendation fr...",
      "latency_seconds": 53.61149716377258,
      "token_count": 192.4,
      "throughput_tokens_per_sec": 3.5887824473966066,
      "cosine_similarity": 0.17925747202087766,
      "precision": 0.3333333333333333,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.42857142857142855,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 148,
      "ground_truth_length_words": 27,
      "length_ratio": 5.481481481481482,
      "has_hallucination": false
    },
    {
      "question_id": 7,
      "question": "What are the criteria for implantable cardioverter-defibrillator (ICD) therapy for primary prevention of sudden cardiac death in patients with heart failure?",
      "answer": " Based on the provided medical documents, the criteria for implantable cardioverter-defibrillator (ICD) therapy for primary prevention of sudden cardiac death in patients with heart failure can be found in the following references:\n\n1. For patients with genetic arrhythmogenic cardiomyopathy and high-risk features of sudden death, with an ejection fraction (EF) of 45%, implantation of ICD is reasonable to decrease sudden death (Reference: 2b B-NR).\n\n2. For patients who have LVEF of 35%, sinus rhythm, a non-Left Bundle Branch Block (LBBB) pattern with QRS duration of 120 to 149 ms, and NYHA class III or ambulatory class IV on guideline-directed medical therapy (GDMT), CRT may be considered to reduce total mortality, reduce hospitalizations, and improve symptoms and quality of life (QOL) (Reference: 2b B-NR).\n\n3. For patients who have LVEF of 30%, ischemic cause of heart failure, sinus rhythm, LBBB with a QRS duration of 150 ms, and NYHA class I symptoms on GDMT, CRT may be considered to reduce hospitalizations and improve symptoms and QOL (Reference: 2b B-NR).\n\nIt's important to note that these recommendations are based on evidence from the provided medical documents. The specific criteria for ICD therapy may vary depending on the individual patient's condition and other factors, so it is essential to consult with a healthcare professional for personalized advice.",
      "ground_truth": "ICD therapy is recommended for primary prevention in patients who are at least 40 days post-myocardial infarction with LVEF \u00e2\u2030\u00a430% and NYHA class I symptoms while receiving GDMT, and who have a reasonable expectation of meaningful survival for >1 year.",
      "context": "arrhythmia. Multicenter Automatic De \ufb01brillator\nImplantation Trial Investigators. N Engl J Med\n1996;335:1933/C0 40.\n5. Buxton AE, Lee KL, Fisher JD, et al. A random-\nized study of the prevention of sudden death in\npatients with coronary artery disease. Multicenter\nUnsustained Tachycardia Trial Investigators. N Engl J\nMed 1999;341:1882/C0 90.\n6. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic\nimplantation of a de\ufb01brillator in patients with myo-\ncardial infarction and reduced ejection fraction. N\n...",
      "latency_seconds": 74.1306300163269,
      "token_count": 278.2,
      "throughput_tokens_per_sec": 3.7528346911219805,
      "cosine_similarity": 0.3534921889651852,
      "precision": 0.6666666666666666,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.4,
      "answer_length_words": 214,
      "ground_truth_length_words": 40,
      "length_ratio": 5.35,
      "has_hallucination": false
    },
    {
      "question_id": 8,
      "question": "What diagnostic biomarker tests are recommended for patients presenting with dyspnea to support or exclude a diagnosis of heart failure?",
      "answer": " Based on the provided medical documents, the diagnostic biomarker tests recommended for patients presenting with dyspnea to support or exclude a diagnosis of heart failure include B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). These tests provide incremental diagnostic value in the ambulatory setting for a suspected cardiac cause of dyspnea when the cause is unclear and the physical examination is equivocal (1/C0 9). In the emergency setting, BNP and NT-proBNP levels have higher sensitivity than specificity and may be more useful for ruling out heart failure than ruling in heart failure. However, it's important to note that increases in both BNP and NT-proBNP levels have been reported in patients with various cardiac and noncardiac causes (Table 6) (50/C0 53). Higher levels of these biomarkers are associated with a greater risk for adverse short- and long-term outcomes in patients with heart failure, including all-cause and cardiovascular death.",
      "ground_truth": "Measurement of B-type natriuretic peptide (BNP) or N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) is useful to support a diagnosis or exclusion of heart failure.",
      "context": "dard exercise testing variables, such as heart rate,\nblood pressure, electrocardiographic \ufb01ndings,\nand symptoms to provide insights into the physio-\nlogic mechanisms underlying a patient\u2019s dyspnea.\nIn particular, CPET can help to distinguish respira-\ntory vs cardiac etiologies of dyspnea. If exercise\ncapacity is diminished but cardiopulmonary\nresponses are normal, other causes of dyspnea,\nsuch as metabolic abnormalities and decondition-\ning, should be considered.\n4.8. Initial and Serial Evaluati...",
      "latency_seconds": 64.55099105834961,
      "token_count": 193.70000000000002,
      "throughput_tokens_per_sec": 3.0007285221215065,
      "cosine_similarity": 0.28476154146186705,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.42857142857142855,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 149,
      "ground_truth_length_words": 25,
      "length_ratio": 5.96,
      "has_hallucination": false
    },
    {
      "question_id": 9,
      "question": "What is the definition of hypertension according to office blood pressure measurements?",
      "answer": " Based on the provided medical documents, the definition of hypertension according to office blood pressure measurements is as follows:\n\n1. Hypertension is classified according to seated office blood pressure (Table 12). The diagnostic thresholds for hypertension are higher than those for home or ambulatory blood pressure monitoring (ABPM or HBPM, Table 13).\n2. Category SBP (systolic blood pressure) and DBP (diastolic blood pressure) values for the different categories of conventionally measured seated office blood pressure are provided in Table 12:\n   - Optimal: <120 mmHg and <80 mmHg\n   - Normal: 120/80 mmHg to 129/84 mmHg\n   - High-normal: 130/85 mmHg to 139/89 mmHg\n   - Grade 1 hypertension: 140/90 mmHg to 159/99 mmHg\n\nIt is important to note that these definitions are based on office blood pressure measurements. However, the guidelines recommend confirming the diagnosis of hypertension with repeated office BP measurements over a number of visits or by 24-h ABPM or HBPM (Figure 14).",
      "ground_truth": "According to Table 12, hypertension is defined as office blood pressure \u00e2\u2030\u00a5140 mmHg systolic and/or \u00e2\u2030\u00a590 mmHg diastolic.",
      "context": ".............................................\n.........................\n4.7.1. Definition and classification of hypertension\nBP is classified according to seated office BP (Table 12), with approxi-\nmately corresponding values according to ABPM or home BP average\nvalues inTable 13.\n4.7.2. Blood pressure measurement\n4.7.2.1 Office blood pressure measurement\nOffice BP should be measured in standardized conditions using\nvalidated auscultatory or (semi)automatic devices, as described in\nTable 14.\n4.7...",
      "latency_seconds": 64.25261521339417,
      "token_count": 197.6,
      "throughput_tokens_per_sec": 3.0753612027111403,
      "cosine_similarity": 0.5672655460020588,
      "precision": 0.2222222222222222,
      "hallucination_entities": [
        "85 mmHg",
        "120 mmHg",
        "99 mmHg"
      ],
      "hallucination_count": 3,
      "contradiction_count": 0,
      "entity_overlap_context": 0.4,
      "entity_overlap_truth": 0.6666666666666666,
      "answer_length_words": 152,
      "ground_truth_length_words": 18,
      "length_ratio": 8.444444444444445,
      "has_hallucination": true
    },
    {
      "question_id": 10,
      "question": "What are the recommended LDL-C (low-density lipoprotein cholesterol) goals for patients with established atherosclerotic cardiovascular disease (ASCVD)?",
      "answer": " Based on the provided medical documents, for patients with established atherosclerotic cardiovascular disease (ASCVD), the recommended LDL-C (low-density lipoprotein cholesterol) goals are as follows:\n\n1. For patients who experience a second vascular event within 2 years while taking maximum tolerated statin-based therapy, an even lower LDL-C goal of <1.0 mmol/L (40 mg/dL) may be considered.\n\n2. In general, the recommended LDL-C levels are determined based on a stepwise treatment intensification approach, considering risk modifiers, lifetime CVD risk, and patient preferences. The specific LDL-C goals according to the level of risk are:\n   - For patients with <5% lifetime CVD risk, no additional prevention goals are recommended.\n   - For patients with \u226510% and <10%, an LDL-C goal of <2.6 mmol/L (100 mg/dL) is suggested.\n   - For patients with 5 to <10%, the specific LDL-C goal isn't explicitly stated, but it would be closer to the lower end of the range compared to those with a lower risk.",
      "ground_truth": "In patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a \u00e2\u2030\u00a550% reduction of LDL-C vs. baseline is recommended.",
      "context": "o fn o n - H D L - Ca sat r e a t m e n tt a r g e ta si tc a p t u r e st h ei n f o r m a t i o n\nregarding all apolipoprotein-B-containing lipoproteins.\n513 We suggest\nit as a reasonable alternative treatment goal for all patients, particularly\nfor those with hypertriglyceridaemia or DM. How non-HDL-C levels\ncorrespond to commonly used LDL-C goals is shown inTable10.\n4.6.1.4 Apolipoprotein B\nApolipoprotein B provides a direct estimate of the total concentra-\ntion of atherogenic lipid particle...",
      "latency_seconds": 66.50172710418701,
      "token_count": 201.5,
      "throughput_tokens_per_sec": 3.0299964944416216,
      "cosine_similarity": 0.3421288638633175,
      "precision": 0.14285714285714285,
      "hallucination_entities": [
        "2.6 mmol/L",
        "100 mg/dL"
      ],
      "hallucination_count": 2,
      "contradiction_count": 0,
      "entity_overlap_context": 0.29411764705882354,
      "entity_overlap_truth": 0.3333333333333333,
      "answer_length_words": 155,
      "ground_truth_length_words": 27,
      "length_ratio": 5.7407407407407405,
      "has_hallucination": true
    },
    {
      "question_id": 11,
      "question": "What is the recommended physical activity for adults to reduce all-cause mortality, CV mortality, and morbidity?",
      "answer": " Based on the provided medical documents, it is recommended for adults of all ages to strive for at least 150 - 300 minutes a week of moderate-intensity or 75 - 150 minutes a week of vigorous-intensity aerobic physical activity. This can be achieved through an equivalent combination of both intensities. Additionally, it is recommended to reduce sedentary time and engage in at least light activity throughout the day. Performing resistance exercise, in addition to aerobic activity, is also recommended on 2 or more days per week to further reduce all-cause mortality. These recommendations are aimed at reducing all-cause mortality, CV mortality, and morbidity.\n\nReferences:\n1. Hillman CH, Jakicic JM, Janz KF, et al. (2018). The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J Phys Act Health\n373. Sattelmair J, Pertman J, Ding EL, et al. (2011). Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation\n374. Hupin D, Roche F, Gremeaux V, et al. (2015). Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged >=60 years: a systematic review and meta-analysis. Br J Sports Med\n375. Ekelund U, Tarp J, Steene-Johannessen J, et al. (2019). Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ",
      "ground_truth": "It is recommended for adults of all ages to strive for at least 150\u00e2\u20ac\u201c300 min a week of moderate-intensity or 75\u00e2\u20ac\u201c150 min a week of vigorous-intensity aerobic physical activity, or an equivalent combination thereof.",
      "context": "It is recommended for adults of all ages to strive\nfor at least 150 - 300 min a week of moderate-\nintensity or 75 - 150 min a week of vigorous-\nintensity aerobic PA, or an equivalent combina-\ntion thereof, to reduce all-cause mortality, CV\nmortality, and morbidity.\n371,372\nIA\nIt is recommended that adults who cannot per-\nform 150 min of moderate-intensity PA a week\nshould stay as active as their abilities and health\ncondition allow.\n373,374\nIB\nIt is recommended to reduce sedentary time to\nengage...",
      "latency_seconds": 84.31987118721008,
      "token_count": 284.7,
      "throughput_tokens_per_sec": 3.3764283079595625,
      "cosine_similarity": 0.40982010841561733,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.2,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 219,
      "ground_truth_length_words": 34,
      "length_ratio": 6.4411764705882355,
      "has_hallucination": false
    },
    {
      "question_id": 12,
      "question": "What is the recommended maximum alcohol consumption per week for cardiovascular disease prevention?",
      "answer": " Based on the provided medical documents, it is recommended that in individuals who drink alcohol, the maximum consumption per week should be limited to 2 standard drinks per day for men and 1 standard drink per day for women for cardiovascular disease prevention. In the United States, one \"standard\" drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol). However, it's important to note that excessive alcohol consumption is linked to hypertension, increased mortality rate, and recurrent cardiovascular events in patients with CCD. Therefore, moderation in alcohol intake is advised for cardioprotection.",
      "ground_truth": "It is recommended to restrict alcohol consumption to a maximum of 100 g per week.",
      "context": "108). \nI A \n6. Adult men and women with elevated BP or hypertension who currently \nconsume alcohol should be advised to drink no more than 2 and 1 standard \ndrinks* per day, respectively (109-114). \nI \nSBP:   \nA \n7. Use of BP-lowering medications is recommended for secondary prevention \nof recurrent CVD events in patients with clinical CVD and an average SBP of \n130 mm Hg or higher or  an average DBP of 80 mm Hg or higher, and  for \nprimary prevention in adults with an estimated 10 -year atheros...",
      "latency_seconds": 48.80844783782959,
      "token_count": 158.6,
      "throughput_tokens_per_sec": 3.249437485227201,
      "cosine_similarity": 0.3566113395698725,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.25,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 122,
      "ground_truth_length_words": 15,
      "length_ratio": 8.133333333333333,
      "has_hallucination": false
    },
    {
      "question_id": 13,
      "question": "According to the 2020 ACC/AHA guidelines, what are the stages of valvular heart disease and their definitions?",
      "answer": " Based on the provided medical documents, the 2020 ACC/AHA guidelines for the management of patients with valvular heart disease classify the disease stages as follows:\n\n1. Stage A: Individuals who are at risk for valvular heart disease but do not have evidence of valve disease or structural heart abnormalities.\n\n2. Stage B: Individuals who have valvular heart disease but are asymptomatic and without evidence of left ventricular (LV) dysfunction, hemodynamic consequences, or abnormal imaging findings beyond those attributable to the valvular heart disease itself.\n\n3. Stage C: Individuals with symptomatic or asymptomatic valvular heart disease who have LV dysfunction, hemodynamic consequences, or evidence of left atrial (LA) enlargement.\n\n4. Stage D: Individuals with refractory symptoms or recurrent severe complications despite optimal medical therapy, or those awaiting transplantation, mechanical circulatory support, or palliative care.\n\nThe guidelines do not provide specific statistics or findings for each stage in the context provided.",
      "ground_truth": "- Stage A (At risk): Patients with risk factors for developing VHD\n- Stage B (Progressive): Patients with progressive VHD (mild to moderate severity and asymptomatic)\n- Stage C (Asymptomatic severe): Asymptomatic patients who meet criteria for severe VHD\n  + C1: Asymptomatic patients with severe VHD in whom the LV or RV remains compensated\n  + C2: Asymptomatic patients with severe VHD with decompensation of LV or RV\n- Stage D (Symptomatic severe): Patients who have developed symptoms as a result of VHD",
      "context": "Top 10 Take Home Messages \n1. Disease stages in patients with valvular heart \ndise\nase should be classified (Stages A, B, C, \nand D) on the basis of symptoms, valve \nanatomy, the severity of valve dysfunction, \nand the response of the ventricle and \npulmonary circulation.\n6\n\nTop 10 Take Home Messages \n2. In the evaluation of a patient with valvular heart disease, history and \nphysical examination findings should be correlated with the results of \nnoninvasive testing (i.e., ECG, chest x-ray, tran...",
      "latency_seconds": 53.14858150482178,
      "token_count": 193.70000000000002,
      "throughput_tokens_per_sec": 3.6444999003863736,
      "cosine_similarity": 0.2695121462732385,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.0,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 149,
      "ground_truth_length_words": 82,
      "length_ratio": 1.8170731707317074,
      "has_hallucination": false
    },
    {
      "question_id": 14,
      "question": "In patients with atrial fibrillation and valvular heart disease, what is the recommended anticoagulation for those with rheumatic mitral stenosis or a mechanical prosthesis?",
      "answer": " Based on the provided medical documents, for patients with atrial fibrillation and either rheumatic mitral stenosis or a mechanical prosthesis, oral anticoagulation with a vitamin K antagonist is recommended. This information can be found in the Top 10 Take Home Messages (point 3) and Anticoagulation for AF in Patients With VHD (point 2a). No specific statistics or findings were provided regarding this recommendation.",
      "ground_truth": "Oral anticoagulation with a vitamin K antagonist is recommended.",
      "context": "Antithrombotic Therapy for Prosthetic Valves\nCOR LOE Recommendations\n1 A\n1. In patients with a mechanical prosthetic valve, anticoagulation with a VKA is\nrecommended.\n1 B-NR\n2. For patients with a mechanical bileaflet or current-generation single-tilting disk AV R\nand no risk factors for thromboembolism, anticoagulation with a VKA to achieve an\nINR of 2.5 is recommended.\n1 B-NR\n3. For patients with a mechanical AV Rand additional risk factors for thromboembolism\n(e.g., AF, previous thromboemboli...",
      "latency_seconds": 25.744154930114746,
      "token_count": 81.9,
      "throughput_tokens_per_sec": 3.1813046581768285,
      "cosine_similarity": 0.3082501011517746,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 63,
      "ground_truth_length_words": 9,
      "length_ratio": 7.0,
      "has_hallucination": false
    },
    {
      "question_id": 15,
      "question": "According to the guidelines, what are the indications for transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR)?",
      "answer": " According to the provided medical documents, the indications for transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) are based on a shared decision-making process that considers the lifetime risks and benefits associated with type of valve (mechanical versus bioprosthetic) and type of approach (transcatheter versus surgical).\n\nFor patients with B AV (bioprosthetic aortic valve) and symptomatic, severe AS (aortic stenosis), TAVI may be considered as an alternative to SAVR after consideration of patient-specific procedural risks, values, trade-offs, and preferences, and when the surgery is performed at a Comprehensive Valve Center.\n\nHowever, the documents do not provide specific statistics or findings that differentiate between TAVI and SAVR indications in detail. It's important to note that the choice of intervention should be individualized based on each patient's unique circumstances.",
      "ground_truth": "- For patients <65 years or life expectancy >20 years: SAVR recommended\n- For patients 65-80 years: Either SAVR or transfemoral TAVI after shared decision-making\n- For patients >80 years or life expectancy <10 years: Transfemoral TAVI recommended in preference to SAVR\n- For high/prohibitive surgical risk: TAVI recommended if predicted survival >12 months",
      "context": "Top 10 Take Home Messages \n6. Indications for transcatheter aortic valve implantation are \nexpanding as a result of multiple randomized trials of \ntranscatheter aortic valve implantation atrio versus surgical \naortic valve replacement.  The choice of type of intervention for \na patient with severe aortic stenosis should be a shared decision-\nmaking process that considers the lifetime risks and benefits \nassociated with type of valve (mechanical versus bioprosthetic) \nand type of approach (transc...",
      "latency_seconds": 38.657201528549194,
      "token_count": 169.0,
      "throughput_tokens_per_sec": 4.371759809752131,
      "cosine_similarity": 0.13136558669501874,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.0,
      "entity_overlap_truth": 0.2857142857142857,
      "answer_length_words": 130,
      "ground_truth_length_words": 54,
      "length_ratio": 2.4074074074074074,
      "has_hallucination": false
    },
    {
      "question_id": 16,
      "question": "What is the recommended management for asymptomatic patients with chronic severe aortic regurgitation and normal LV systolic function (Stage C1)?",
      "answer": " Based on the provided medical documents, for asymptomatic patients with chronic severe aortic regurgitation (AR) and normal LV systolic function (Stage C1), aortic valve surgery may be considered when there is a progressive decline in LVEF on at least 3 serial studies to the low\u2013normal range (LVEF 55% to 60%) or a progressive increase in LV dilation into the severe range (LV end-diastolic dimension [LVEDD] >65 mm). However, if the patient is normotensive and has normal LV systolic function, vasodilator therapy is not indicated.",
      "ground_truth": "- Aortic valve surgery is indicated if undergoing cardiac surgery for other indications\n- In patients with low surgical risk, surgery may be considered with progressive decline in LVEF to 55-60% on \u00e2\u2030\u00a53 studies or progressive LV dilation (LVEDD >65 mm)",
      "context": "Timing of Intervention for Patients with Chronic AR\nCOR LOE Recommendations\n1 B-NR 1. In symptomatic patients with severe AR (Stage D), aortic valve surgery\nis indicated regardless of LV systolic function.\n1 B-NR\n2. In asymptomatic patients with chronic severe AR and LV systolic\ndysfunction (LVEF \u226455%) (Stage C2), aortic valve surgery is indicated\nif no other cause for systolic dysfunction is identified.\n1 C-EO 3. In patients with severe AR (Stage C or D) who are undergoing cardiac\nsurgery for o...",
      "latency_seconds": 30.572582006454468,
      "token_count": 109.2,
      "throughput_tokens_per_sec": 3.571827854675335,
      "cosine_similarity": 0.4197719737914349,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.5,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 84,
      "ground_truth_length_words": 41,
      "length_ratio": 2.048780487804878,
      "has_hallucination": false
    },
    {
      "question_id": 17,
      "question": "For an adult patient with hypertension and chronic kidney disease, what blood pressure treatment goal is recommended in the 2017 ACC/AHA guideline, as adapted in the 2019 document?",
      "answer": " Based on the provided medical documents, for an adult patient with hypertension and chronic kidney disease, the blood pressure treatment goal recommended in the 2017 ACC/AHA guideline, as adapted in the 2019 document, is less than 130/80 mm Hg. This recommendation is derived from point 9 in the context: \"Adults with hypertension and CKD should be treated to a BP goal of less than 130/80 mm Hg (128-133).\"",
      "ground_truth": "Treatment to a BP goal of less than 130/80 mm Hg is recommended.",
      "context": "18 \n \nI \nSBP:  \nB-RSR \n4. In adults with hypertension and chronic kidney disease, treatment to a BP goal of \nless than 130/80 mm Hg is recommended (128-133).  \n \nAdapted from recommendations in the 2017 \nACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the \nPrevention, Detection, Evaluation, and Management of High Blood Pressure in Adults \n(12). \nDBP:  \nC-EO \nI \nSBP:  \nB-RSR \n5. In adults with T2DM and hypertension, antihypertensive drug treatment should be \ninitiated at a BP of 13...",
      "latency_seconds": 46.90036201477051,
      "token_count": 88.4,
      "throughput_tokens_per_sec": 1.884846858370941,
      "cosine_similarity": 0.414965895205907,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 68,
      "ground_truth_length_words": 13,
      "length_ratio": 5.230769230769231,
      "has_hallucination": false
    },
    {
      "question_id": 18,
      "question": "For primary prevention in a 40-75 year old adult with diabetes mellitus, what intensity of statin therapy is recommended by the 2018 Cholesterol Guideline, regardless of their estimated 10-year ASCVD risk?",
      "answer": " Based on the provided medical documents, for primary prevention in a 40-75 year old adult with diabetes mellitus, moderate-intensity statin therapy is indicated regardless of their estimated 10-year ASCVD risk, as stated in section I A 3 from the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (9).",
      "ground_truth": "Moderate-intensity statin therapy is indicated.",
      "context": "or more (148, 151-156). \nAdapted from recommendations in the 2018 \nAHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the \nManagement of Blood Cholesterol (9). \nI A \n3. In adults 40 to 75 years of age with diabetes, regardless of estimated 10-year ASCVD \nrisk, moderate-intensity statin therapy is indicated (157-165).  \nIncluded from recommendations in the 2018 \nAHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the \nManagement of Blood Cholesterol (9). \nI B-R ...",
      "latency_seconds": 49.2683322429657,
      "token_count": 63.7,
      "throughput_tokens_per_sec": 1.2929197539276316,
      "cosine_similarity": 0.20975539627821702,
      "precision": 0.3333333333333333,
      "hallucination_entities": [
        "75 year"
      ],
      "hallucination_count": 1,
      "contradiction_count": 0,
      "entity_overlap_context": 0.1,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 49,
      "ground_truth_length_words": 5,
      "length_ratio": 9.8,
      "has_hallucination": true
    }
  ],
  "olmo2:latest": [
    {
      "question_id": 1,
      "question": "What is the recommended first-line therapy for lipid lowering in patients with chronic coronary disease (CCD), and what is the target LDL-C reduction?",
      "answer": "Based on the provided medical documents, the recommended first-line therapy for lipid lowering in patients with chronic coronary disease (CCD) is a high-intensity statin prescribed up to the highest tolerated dose. This approach aims to achieve an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and an LDL-C reduction of >50% from baseline, as recommended for apparently healthy persons <70 years at very high risk (as outlined in the provided context).\n\nThe documents emphasize that high-intensity statin therapy is the preferred initial approach due to its established efficacy and safety in reducing LDL-C levels by 50% and reducing cardiovascular morbidity and mortality rates, as shown in Figure 8 referenced within the documents. The goal of LDL-C reduction is defined as a percentage response relative to baseline levels, with reductions expected to occur within 4 to 12 weeks after initiation or change in lipid-lowering therapy.\n\nThe documents also highlight that while statins are the first-line treatment, other therapies such as ezetimibe, PCSK9 monoclonal antibodies, and icapent ethyl can be considered when additional LDL-C lowering is necessary, especially if high-intensity statins are not well tolerated or effective in achieving desired LDL-C levels. However, the primary recommendation for patients with CCD remains high-intensity statin therapy to meet the specified LDL-C reduction targets.\n\nMonitoring lipid levels every 3 to 12 months is advised to assess individual response to therapy and ensure adherence and persistence with treatment over time. This monitoring is essential for adjusting therapy as needed to maintain the desired LDL-C levels and reduce cardiovascular risk effectively.",
      "ground_truth": "Statins remain first-line therapy for lipid lowering in patients with CCD. The aim with high-intensity statin therapy is to achieve a \u00e2\u2030\u00a550% reduction in LDL-C levels to reduce the risk of major adverse cardiovascular events (MACE). For patients in whom high-intensity statin therapy is contraindicated or not tolerated, moderate-intensity statin therapy is recommended with the aim of achieving a 30% to 49% reduction in LDL-C levels.",
      "context": "The expected LDL-C reductions in response to therapy are\nshown in Figure 13, and may vary widely among individuals.\nTherefore, monitoring the effect on LDL-C levels is recommended,\nwith assessment of LDL-C levels 4 - 6 weeks after any treatment\nstrategy initiation or change.\nTreatment Average LDL-C reduction\nIntensity of lipid-lowering treatment\nModerate-intensity statin\nHigh-intensity statin\nHigh-intensity statin plus ezetimibe\nPCSK9 inhibitor\nPCSK9 inhibitor plus high-intensity statin\nPCSK9 in...",
      "latency_seconds": 104.83815240859985,
      "token_count": 330.2,
      "throughput_tokens_per_sec": 3.14961674174748,
      "cosine_similarity": 0.6030055669030413,
      "precision": 0.2857142857142857,
      "hallucination_entities": [
        "12 months"
      ],
      "hallucination_count": 1,
      "contradiction_count": 0,
      "entity_overlap_context": 0.35294117647058826,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 254,
      "ground_truth_length_words": 66,
      "length_ratio": 3.8484848484848486,
      "has_hallucination": true
    },
    {
      "question_id": 2,
      "question": "When is long-term beta-blocker therapy NOT recommended for improving outcomes in patients with chronic coronary disease?",
      "answer": "Based on the provided medical documents, long-term beta-blocker therapy is NOT recommended for improving outcomes in patients with chronic coronary disease (CCD) without previous myocardial infarction (MI) or with left ventricular ejection fraction (LVEF) \u226550%. This recommendation stems from several key points:\n\n1. **Evidence Gap for Patients Without MI or LVEF \u226550%**: The documents emphasize that the strongest data supporting the benefits of beta-blocker therapy in CCD are for patients with LV systolic dysfunction (LVEF \u226450%). There is a lack of clear evidence showing similar benefits for patients with CCD who have not experienced an MI and have LVEF \u226550%. This is highlighted by the absence of significant reductions in major adverse cardiovascular events (MACE) among these patient groups.\n\n2. **REACH Registry Findings**: The REACH registry, which studied patients with CAD without a history of MI, found that beta-blocker therapy did not significantly reduce event rates for the primary endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke among this population.\n\n3. **DANBLOCK Trial and Similar Ongoing Trials**: There are ongoing randomized controlled trials (e.g., REBOOT-CNIC, REDUCE-SWEDEHEART, BETAMI, and DANBLOCK) aimed at providing more clarity on the efficacy, safety, and quality of life associated with beta-blocker therapy in patients with CCD. However, these trials have not yet provided conclusive evidence supporting the use of beta-blockers in patients without MI or LVEF \u226550%.\n\n4. **Guideline Recommendations**: The 2022 AHA/ACC/HFSA guideline for the management of heart failure and the 2021 ACC/AHA/SCAI guideline for coronary artery revascularization provide specific recommendations based on the evidence available. They suggest that beta-blocker therapy should be considered in patients with CCD primarily when there is a clear indication such as LV systolic dysfunction (LVEF \u226450%) or other primary indications like angina, uncontrolled hypertension, or arrhythmias. For patients without these indications, beta-blocker therapy may not offer the same level of benefit.\n\nIn summary, based on the provided medical documents and the evidence from clinical trials and guidelines, long-term beta-blocker therapy is NOT recommended for improving outcomes in patients with chronic coronary disease who do not have a previous history of myocardial infarction or who have an LVEF of \u226550%. This recommendation is grounded in the lack of clear evidence supporting the use of beta-blockers in these patient populations and the potential absence of clinical benefit.",
      "ground_truth": "Long-term beta-blocker therapy is not recommended to improve outcomes in patients with CCD in the absence of myocardial infarction in the past year, left ventricular ejection fraction \u00e2\u2030\u00a450%, or another primary indication for beta-blocker therapy (such as angina, uncontrolled hypertension, or arrhythmias).",
      "context": "era. Other primary indications for beta blockers may\ninclude their use for angina, uncontrolled hypertension,\nor arrhythmias. A comprehensive screening as well as\nassessment of their symptoms and comorbid conditions\nis recommended given that beta-blocker therapy may still\nbe indicated for its antianginal properties (see Section\n4.3.6 ), antihypertensive properties (see Section 4.2.7 ,\n\u201cBlood Pressure Management \u201d), or for its negative chro-\nnotropic effects among patients with rhythm disturbance...",
      "latency_seconds": 136.02129530906677,
      "token_count": 490.1,
      "throughput_tokens_per_sec": 3.6031122838993537,
      "cosine_similarity": 0.542488850107903,
      "precision": 0.5714285714285714,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.5384615384615384,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 377,
      "ground_truth_length_words": 42,
      "length_ratio": 8.976190476190476,
      "has_hallucination": true
    },
    {
      "question_id": 3,
      "question": "For patients with CCD and type 2 diabetes, what two classes of glucose-lowering medications are recommended to reduce cardiovascular risk?",
      "answer": "For patients with CCD (cardiovascular disease) and type 2 diabetes, two classes of glucose-lowering medications that are recommended to reduce cardiovascular risk are SGLT2 inhibitors and GLP-1 receptor agonists. \n\n**SGLT2 Inhibitors:** These medications, such as empagliflozin, dapagliflozin, and canagliflozin, have been shown to significantly reduce the risk of major adverse cardiovascular events (MACE), including heart failure hospitalizations, independently of their effects on glycemic control. A meta-analysis published in JAMA Cardiology (Reference 7) demonstrated that SGLT2 inhibitors reduced cardiovascular and kidney outcomes in patients with type 2 diabetes. The EMPA-REG OUTCOME trial (Reference 8) further supported this finding, showing that empagliflozin led to a 37% reduction in the primary composite endpoint of cardiovascular death, heart failure hospitalization, and nonfatal myocardial infarction in patients with type 2 diabetes and established cardiovascular disease.\n\n**GLP-1 Receptor Agonists:** Medications like liraglutide, semaglutide, and dulaglutide have been shown to primarily reduce the risk of atherosclerotic events such as MI and stroke. The N Engl J Med studies (References 9-13) demonstrated that GLP-1 receptor agonists, including liraglutide and semaglutide, reduced cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease. For instance, the LIRAGLUTIDE IN T2D AND ACUTE CORONARY SYNDROME trial (Reference 11) showed that liraglutide reduced the risk of cardiovascular death, MI, and stroke in patients with type 2 diabetes and acute coronary syndrome.\n\nBoth SGLT2 inhibitors and GLP-1 receptor agonists improve glycemic control, facilitate weight loss, reduce progression of kidney disease, and reduce the risk of cardiovascular events through distinct pathways. However, their adoption in clinical practice has been slow (Reference 35), highlighting an opportunity for cardiovascular specialists to have a greater collaborative role in the care of patients with CCD and type 2 diabetes.\n\nIn summary, based on the provided medical documents, both SGLT2 inhibitors and GLP-1 receptor agonists are recommended for reducing cardiovascular risk in patients with CCD and type 2 diabetes. The use of these medications is projected to be of high value (Reference 2) or intermediate value (References 3 and 5) compared with standard of care, depending on the specific context such as the presence of heart failure or other conditions.",
      "ground_truth": "For patients with CCD who have type 2 diabetes, the use of either a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended to reduce the risk of MACE. These benefits are independent of their effects on glycemic control.",
      "context": "irrespective of diabetes status, is projected to be of uncertain value at US prices.30\n*Modi\ufb01ed from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.31\nSynopsis\nComprehensive cardiovascular risk reduction strategies\nare effective in patients with CCD and type 2 diabetes.32\nDespite these efforts, cardio vascular event rates remain\nhigh among patients with type 2 diabetes, even among\nwell-managed patients,\n1,10,33 and CAD remains the leading\ncause of morbidity and death. 34 Two...",
      "latency_seconds": 146.35759162902832,
      "token_count": 456.3,
      "throughput_tokens_per_sec": 3.117706399245628,
      "cosine_similarity": 0.4268893797516675,
      "precision": 0.4,
      "hallucination_entities": [
        "myocardial infarction"
      ],
      "hallucination_count": 1,
      "contradiction_count": 0,
      "entity_overlap_context": 0.4,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 351,
      "ground_truth_length_words": 48,
      "length_ratio": 7.3125,
      "has_hallucination": true
    },
    {
      "question_id": 4,
      "question": "In patients with CCD and angina, what are the recommended first-line anti-anginal therapies for symptom relief?",
      "answer": "Based on the provided medical documents, the recommended first-line anti-anginal therapies for symptom relief in patients with Chronic Coronary Artery Disease (CCD) and angina are:\n\n1. **Beta blockers**: These are considered the first antianginal therapy to use in patients with symptomatic CCD. The evidence basis for this prioritization is not strong, but early randomized, placebo-controlled studies have found that beta blockers can reduce anginal symptoms. However, it's noted that full freedom from angina is only achieved in 40% to 50%, depending on the frequency of anginal episodes at the onset of treatment.\n\n2. **Nitrates (sublingual nitroglycerin or nitroglycerin spray)**: For patients with CCD and normal left ventricular function, sublingual nitroglycerin or nitroglycerin spray is recommended for immediate short-term relief of angina or equivalent symptoms. This recommendation is based on the guidelines provided in the context, which state that nitrates are recommended for immediate short-term relief of angina.\n\n3. **Calcium Channel Blockers (CCBs)**: Specifically, non-dihydropyridine CCBs like nifedipine have been studied and shown to be effective in relieving anginal symptoms in controlled clinical trials. For example, a double-blind placebo-controlled crossover trial by Sherman et al. (1983) demonstrated the efficacy of nifedipine in stable exertional angina.\n\n4. **Ivabradine**: This selective cardiac IKr blocker is recommended for patients with CCD and normal left ventricular function, but it's also mentioned that its use may be potentially harmful due to a lack of clear evidence regarding its effectiveness and the risk of exacerbating congestive heart failure in some patients.\n\nThe documents emphasize that the choice among these therapies should consider factors such as comorbidities, interactions with other medications, and patient tolerance. The overriding goal is to maximize symptom relief while minimizing the risk of exacerbating comorbidities and ensuring good tolerance and compatibility with other treatments.\n\nIt's important to note that recommendations for patients with refractory angina (anginal symptoms uncontrolled despite intensive medical therapy) are more limited due to the small size of this patient population and the lack of strong evidence-based guidelines. Options such as enhanced external counterpulsation, direct transmyocardial laser revascularization, and lifestyle modifications are mentioned but are not recommended with Class 1 evidence.\n\nThe provided context does not mention ranolazine, which is another antianginal agent sometimes considered for use in patients with CCD; however, its mechanism of action and effectiveness are not detailed in the given documents. Therefore, based strictly on the provided medical documents, beta blockers, nitrates, and non-dihydropyridine CCBs are the recommended first-line therapies for symptom relief in patients with CCD and angina.",
      "ground_truth": "In patients with CCD and angina, anti-anginal therapy with either a beta blocker, calcium channel blocker (CCB), or long-acting nitrate is recommended for relief of angina or equivalent symptoms. Either a calcium channel blocker or beta blocker is recommended as first-line antianginal therapy.",
      "context": "with beta blockers, CCB, or long-acting nitrate therapies. *7,8\n1 B-NR\n4. In patients with CCD, sublingual nitroglycerin or nitroglycerin spray is recommended for immediate\nshort-term relief of angina or equivalent symptoms. *9,10\n3: Harm B-R\n5. In patients with CCD and normal LV function, the addition of ivabradine to standard anti-anginal therapy\nis potentially harmful. *11\n*Modi\ufb01ed from the 2012 ACC/AHA Multisociety Guideline for the Diagnosis and Management of Patients With SIHD.12\nSynopsis\n...",
      "latency_seconds": 146.46536803245544,
      "token_count": 535.6,
      "throughput_tokens_per_sec": 3.6568371567626534,
      "cosine_similarity": 0.3332088552645075,
      "precision": 0.5,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.16666666666666666,
      "entity_overlap_truth": 0.2,
      "answer_length_words": 412,
      "ground_truth_length_words": 43,
      "length_ratio": 9.581395348837209,
      "has_hallucination": true
    },
    {
      "question_id": 5,
      "question": "What are the four medication classes that make up guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) according to the 2022 guidelines?",
      "answer": "Based on the provided medical documents, the four medication classes that make up guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) according to the 2022 guidelines are:\n\n1. **ACE Inhibitors (or Angiotensin Receptor Blockers):** These medications help reduce the workload on the heart and lower blood pressure. The evidence review conducted from May 2020 to December 2020 highlighted their effectiveness in improving outcomes for patients with HFrEF.\n\n   *Evidence:* \"ACE-inhibitors, angiotensin and neprilysin receptor antagonist; sacubitril valsartan\" (from document 24).\n\n2. **Mineralocorticoid Receptor Antagonists (MRA):** These drugs help reduce the retention of sodium and water by the kidneys, which can decrease blood volume and pressure on the heart.\n\n   *Evidence:* \"MRA; sodium glucose co-transporter 2 or SGLT2 inhibitors\" (from document 1).\n\n3. **Beta Blockers:** These medications help reduce the heart rate and the workload on the heart, which can improve symptoms and reduce the risk of hospitalization for patients with HFrEF.\n\n   *Evidence:* \"beta blockers\" (from document 1).\n\n4. **Sodium Glucose Co-Transporter 2 Inhibitors (SGLT2i):** These drugs help reduce the kidneys' reabsorption of glucose and sodium, leading to increased excretion of both, which can decrease blood volume and pressure on the heart.\n\n   *Evidence:* \"SGLT2i\" (from document 1).\n\nThe documents emphasize that these classes of medications should be tailored to the individual patient based on their specific clinical scenario, comorbidities, and potential contraindications. The guidelines also note that there is limited evidence regarding the treatment strategy for patients whose left ventricular ejection fraction (LVEF) improves from mildly reduced to greater than 50%, suggesting a need for further research in this area.\n\nThe recommendations are based on an extensive evidence review conducted by the American College of Cardiology Foundation and the American Heart Association, indicating that these medication classes have been shown to be effective through rigorous clinical trials and studies.",
      "ground_truth": "1. Sodium-glucose cotransporter-2 inhibitors (SGLT2i)\n2. Angiotensin receptor-neprilysin inhibitors (ARNi), angiotensin-converting enzyme inhibitors (ACEi), or angiotensin II receptor blockers (ARB)\n3. Beta blockers\n4. Mineralocorticoid receptor antagonists (MRA)",
      "context": "Titration of medical therapy for heart failure with\nreduced ejection fraction. J Am Coll Cardiol\n2019;73:2365/C0 83.\n23. Yancy CW, Januzzi Jr. JL, Allen LA, et al. 2017\nACC expert consensus decision pathway for optimi-\nzation of heart failure treatment: answers to 10 piv-\notal issues about heart failure with reduced ejection\nfraction: a report of the American College of Cardi-\nology Task Force on Expert Consensus Decision Path-\nways. J Am Coll Cardiol 2018;71:201/C0 30.\n24. Bhagat AA, Greene SJ,...",
      "latency_seconds": 116.47270226478577,
      "token_count": 390.0,
      "throughput_tokens_per_sec": 3.3484240720489593,
      "cosine_similarity": 0.13667653684357892,
      "precision": 0.5,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.4,
      "entity_overlap_truth": 0.4,
      "answer_length_words": 300,
      "ground_truth_length_words": 28,
      "length_ratio": 10.714285714285714,
      "has_hallucination": true
    },
    {
      "question_id": 6,
      "question": "How is heart failure with preserved ejection fraction (HFpEF) defined in terms of left ventricular ejection fraction (LVEF) percentage?",
      "answer": "Based on the provided medical documents, heart failure with preserved ejection fraction (HFpEF) is defined as a condition where the left ventricular ejection fraction (LVEF) percentage remains at or above 45%. This definition is supported by several pieces of evidence from the documents:\n\n1. **ESC Guidelines (2016)**: The 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure state that HFpEF is characterized by an LVEF \u2265 45% [Ponikowski et al., Rev Esp Cardiol (Engl Ed) 2016;69:1167].\n\n2. **Diagnostic Algorithm for Classifying HF Based on LVEF (2019)**: The HFA-PEFF diagnostic algorithm proposed by Pieske et al. in 2019 categorizes heart failure with preserved ejection fraction as having an LVEF \u2265 45% [Pieske et al., Eur Heart J 2019;40:3297/C0 317].\n\n3. **Clinical Practice Guidelines (2022)**: The 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure reaffirms that HFpEF is defined as an LVEF \u2265 45% [Heidenreich et al., Circulation 2022;143:e254/C0 743].\n\nThese guidelines and documents emphasize the importance of measuring LVEF to differentiate between heart failure with reduced ejection fraction (HFrEF) and HFpEF, as both conditions have distinct clinical presentations and management strategies.\n\nThe documents also provide insights into the epidemiology, diagnostic algorithms, treatment implications, and disparities in HFpEF, but the central definition of HFpEF in terms of LVEF percentage is consistently provided by the sources listed above.",
      "ground_truth": "HFpEF is defined as LVEF \u00e2\u2030\u00a550% with evidence of spontaneous or provokable increased left ventricular filling pressures (e.g., elevated natriuretic peptide levels, noninvasive or invasive hemodynamic measurements).",
      "context": "of the H2F-PEF model in diagnosing patients with\nheart failure and preserved ejection fraction. Circu-\nlation 2019;139:2377/C0 2379.\n7. Selvaraj S, Myhre PL, Vaduganathan M, et al.\nApplication of diagnostic algorithms for heart fail-\nure with preserved ejection fraction to the commu-\nnity. JACC Heart Fail 2020;8:640/C0 53.\n8. Pieske B, Tschope C, de Boer RA, et al. How to\ndiagnose heart failure with preserved ejection frac-\ntion: the HFA-PEFF diagnostic algorithm: a consen-\nsus recommendation fr...",
      "latency_seconds": 91.01348376274109,
      "token_count": 287.3,
      "throughput_tokens_per_sec": 3.1566751224351473,
      "cosine_similarity": 0.16045799494786928,
      "precision": 0.3333333333333333,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.42857142857142855,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 221,
      "ground_truth_length_words": 27,
      "length_ratio": 8.185185185185185,
      "has_hallucination": false
    },
    {
      "question_id": 7,
      "question": "What are the criteria for implantable cardioverter-defibrillator (ICD) therapy for primary prevention of sudden cardiac death in patients with heart failure?",
      "answer": "Based on the provided medical documents, the criteria for implantable cardioverter-defibrillator (ICD) therapy for primary prevention of sudden cardiac death in patients with heart failure are as follows:\n\n1. **Genetic Arrhythmogenic Cardiomyopathy with High-Risk Features of Sudden Death**: For patients with genetic arrhythmogenic cardiomyopathy and high-risk features of sudden death, particularly those with an ejection fraction (EF) of 45% or higher, implantation of an ICD is considered reasonable to decrease the risk of sudden death. This recommendation is supported by studies indicating that ICDs can reduce the incidence of sudden cardiac death in these high-risk populations.\n\n2. **LVEF Between 30% and 35% with Specific Echocardiographic and Clinical Characteristics**: For patients with heart failure (HFrEF) who have an LVEF between 30% and 35%, and specific echocardiographic and clinical characteristics such as a non-LBBB pattern with a QRS duration of 120 to 149 ms, and New York Heart Association (NYHA) class III or ambulatory class IV symptoms on guideline-directed medical therapy (GDMT), CRT may be considered. This is supported by evidence suggesting that CRT can reduce total mortality, hospitalizations, and improve symptoms and quality of life (QOL) in these patients.\n\n3. **LVEF Between 30% and 35% with Sinus Rhythm and Specific Echocardiographic Features**: For patients with HFrEF, sinus rhythm, a non-LBBB pattern with a QRS duration of 120 to 149 ms, and NYHA class I or II symptoms on GDMT, CRT may also be considered if they have an LVEF between 30% and 35%. This recommendation is based on evidence indicating that CRT can reduce hospitalizations and improve symptoms and QOL in these patients.\n\n4. **QRS Duration of <120 ms and NYHA Class I or II Symptoms**: For patients with a QRS duration less than 120 ms and NYHA class I or II symptoms, CRT is not recommended because these patients are not expected to derive significant benefit from the therapy.\n\n5. **No Benefit for Patients with LVEF >50% or QRS Duration <120 ms**: There is no recommendation for CRT in patients with an LVEF greater than 50% or a QRS duration less than 120 ms, as these patients are not considered to be at high risk for sudden cardiac death and would not likely benefit from the therapy.\n\nThese criteria are derived from a comprehensive evidence review conducted from May 2020 to December 2020, focusing on studies published in English and indexed in relevant medical databases. The recommendations are based on the latest guidelines from the European Society of Cardiology (ESC) and are tailored to patients with heart failure, considering their specific clinical characteristics and treatment goals.",
      "ground_truth": "ICD therapy is recommended for primary prevention in patients who are at least 40 days post-myocardial infarction with LVEF \u00e2\u2030\u00a430% and NYHA class I symptoms while receiving GDMT, and who have a reasonable expectation of meaningful survival for >1 year.",
      "context": "arrhythmia. Multicenter Automatic De \ufb01brillator\nImplantation Trial Investigators. N Engl J Med\n1996;335:1933/C0 40.\n5. Buxton AE, Lee KL, Fisher JD, et al. A random-\nized study of the prevention of sudden death in\npatients with coronary artery disease. Multicenter\nUnsustained Tachycardia Trial Investigators. N Engl J\nMed 1999;341:1882/C0 90.\n6. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic\nimplantation of a de\ufb01brillator in patients with myo-\ncardial infarction and reduced ejection fraction. N\n...",
      "latency_seconds": 143.85489177703857,
      "token_count": 553.8000000000001,
      "throughput_tokens_per_sec": 3.8497126733676703,
      "cosine_similarity": 0.37013512658917647,
      "precision": 0.6666666666666666,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.4,
      "answer_length_words": 426,
      "ground_truth_length_words": 40,
      "length_ratio": 10.65,
      "has_hallucination": true
    },
    {
      "question_id": 8,
      "question": "What diagnostic biomarker tests are recommended for patients presenting with dyspnea to support or exclude a diagnosis of heart failure?",
      "answer": "Based on the provided medical documents, the following diagnostic biomarker tests are recommended for patients presenting with dyspnea to support or exclude a diagnosis of heart failure:\n\n1. **BNP (Brain Natriuretic Peptide) and NT-proBNP (N-terminal Pro-BNP):** These markers provide incremental diagnostic value when the cause of dyspnea is unclear and the physical examination is equivocal. In the emergency setting, BNP and NT-proBNP levels have higher sensitivity than specificity for ruling out heart failure (HF). While lower levels of BNP and NT-proBNP may help exclude the presence of HF, higher levels have a high positive predictive value to diagnose HF. However, it's important to note that increases in both BNP and NT-proBNP levels can be seen in patients with various cardiac and noncardiac causes (as referenced in points 50/C0 53 from the provided context).\n\n2. **sST2:** This marker, also mentioned in point 47 of the context, has been shown to predict outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T (point 48). It provides incremental prognostic information over natriuretic peptides but lacks evidence for an incremental management benefit (point 13/C0 40).\n\n3. **Cardiopulmonary Exercise Testing (CPET):** This test assesses heart rate, blood pressure, electrocardiographic findings, and symptoms during exercise to provide insights into the physiological mechanisms underlying a patient\u2019s dyspnea. It can help distinguish between respiratory vs. cardiac etiologies of dyspnea (point 18). In patients with heart failure with preserved ejection fraction (HFpEF), CPET hemodynamic correlates and diagnostic role have been studied (point 19/C0 20 and point 22).\n\n4. **Echocardiography:** This is a crucial tool for diagnosing heart failure, as it allows for the assessment of left ventricular function, size, and presence of valvular heart disease (not explicitly mentioned in the provided context but implied by the discussion around HF diagnosis and exclusion). It is recommended to rule out significant heart valve disease or cardiac ischemia when suspecting HFpEF (point 6).\n\n5. **Other Biomarkers:** While not specifically mentioned in the provided context, other biomarkers such as markers of myocardial injury, inflammation, oxidative stress, vascular dysfunction, and matrix remodeling are suggested to provide incremental prognostic information over natriuretic peptides (points 13/C0 40 and 45/C0 49). However, there is a lack of evidence for an incremental management benefit from these markers.\n\nIn summary, BNP and NT-proBNP levels, along with sST2, are recommended as primary diagnostic tests for dyspnea to support or exclude a diagnosis of heart failure. Cardiopulmonary exercise testing and echocardiography are also valuable tools in the diagnostic process, providing further insights into the underlying cause of dyspnea. Other biomarkers may offer additional prognostic information but do not have evidence supporting their use for guiding treatment decisions.",
      "ground_truth": "Measurement of B-type natriuretic peptide (BNP) or N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) is useful to support a diagnosis or exclusion of heart failure.",
      "context": "dard exercise testing variables, such as heart rate,\nblood pressure, electrocardiographic \ufb01ndings,\nand symptoms to provide insights into the physio-\nlogic mechanisms underlying a patient\u2019s dyspnea.\nIn particular, CPET can help to distinguish respira-\ntory vs cardiac etiologies of dyspnea. If exercise\ncapacity is diminished but cardiopulmonary\nresponses are normal, other causes of dyspnea,\nsuch as metabolic abnormalities and decondition-\ning, should be considered.\n4.8. Initial and Serial Evaluati...",
      "latency_seconds": 162.5846610069275,
      "token_count": 568.1,
      "throughput_tokens_per_sec": 3.4941795645518745,
      "cosine_similarity": 0.26554001818744555,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.42857142857142855,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 437,
      "ground_truth_length_words": 25,
      "length_ratio": 17.48,
      "has_hallucination": true
    },
    {
      "question_id": 9,
      "question": "What is the definition of hypertension according to office blood pressure measurements?",
      "answer": "Based on the provided medical documents, hypertension is defined as a systolic blood pressure (SBP) of \u2265140 mmHg or a diastolic blood pressure (DBP) of \u226590 mmHg measured in a seated position in the office using a validated auscultatory or (semi)automatic device, as described in Table 12. According to the ESC Guidelines 2021, the categories for conventionally measured seated office blood pressure are:\n\n- Optimal: <120/80 mmHg\n- Normal: 120/80 mmHg to <130/85 mmHg\n- High-normal: 130/85 mmHg to <140/90 mmHg\n- Grade 1 hypertension: 140/90 mmHg to <159/99 mmHg\n\nThe documents also mention the classifications for diagnosing hypertension based on ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM), which have lower diagnostic thresholds compared to office BP measurements. For example, the diagnosis of hypertension is made at lower levels with ABPM or HBPM:\n\n- Hypertension: \u2265140/90 mmHg (office BP)\n- Consider masked hypertension: \u2265130/85 mmHg (ABPM or HBPM)\n\nFurthermore, the documents discuss conditions such as white-coat hypertension and masked hypertension, which are identified through the discrepancy between office BP measurements and ABPM or HBPM readings. White-coat hypertension refers to elevated office BP that is normal outside the clinical setting, while masked hypertension involves a normal office BP but elevated BP measured by ABPM or HBPM, indicating a higher risk of cardiovascular disease.\n\nThe guidelines also recommend periodic BP measurement using ABPM or HBPM for individuals with high-normal office BP (130/85 mmHg to <140/90 mmHg) to identify those at risk for masked hypertension and to monitor the progression to sustained hypertension. This approach is recommended due to the better prognostic value of ABPM or HBPM in predicting hypertension-mediated organ damage and clinical outcomes compared to office BP measurements.",
      "ground_truth": "According to Table 12, hypertension is defined as office blood pressure \u00e2\u2030\u00a5140 mmHg systolic and/or \u00e2\u2030\u00a590 mmHg diastolic.",
      "context": ".............................................\n.........................\n4.7.1. Definition and classification of hypertension\nBP is classified according to seated office BP (Table 12), with approxi-\nmately corresponding values according to ABPM or home BP average\nvalues inTable 13.\n4.7.2. Blood pressure measurement\n4.7.2.1 Office blood pressure measurement\nOffice BP should be measured in standardized conditions using\nvalidated auscultatory or (semi)automatic devices, as described in\nTable 14.\n4.7...",
      "latency_seconds": 109.73339414596558,
      "token_count": 365.3,
      "throughput_tokens_per_sec": 3.3289774989925482,
      "cosine_similarity": 0.5025622391346966,
      "precision": 0.42857142857142855,
      "hallucination_entities": [
        "85 mmHg",
        "99 mmHg"
      ],
      "hallucination_count": 2,
      "contradiction_count": 1,
      "entity_overlap_context": 0.26666666666666666,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 281,
      "ground_truth_length_words": 18,
      "length_ratio": 15.61111111111111,
      "has_hallucination": true
    },
    {
      "question_id": 10,
      "question": "What are the recommended LDL-C (low-density lipoprotein cholesterol) goals for patients with established atherosclerotic cardiovascular disease (ASCVD)?",
      "answer": "Based on the provided medical documents from the ASCPD/NLA/PCNA guideline on the management of blood cholesterol and the 2019 ESC/European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidaemias, the recommended LDL-C (low-density lipoprotein cholesterol) goals for patients with established atherosclerotic cardiovascular disease (ASCVD) are as follows:\n\n1. **General LDL-C Goals**:\n   - For apparently healthy people at high or very high CVD risk and patients with established ASCVD and/or DM, a stepwise treatment-intensi\ufb01cation approach is recommended. This approach focuses on achieving LDL-C levels as close as possible to the given goals.\n   - The guidelines do not specify a single universal LDL-C target for all patients with ASCVD due to individual patient factors such as comorbidities, treatment tolerance, and patient preferences. However, they emphasize a stepwise approach that intensifies treatment based on anticipated benefit, side-effects, and patient preferences.\n\n2. **Specific LDL-C Targets**:\n   - For patients with ASCVD who experience a second vascular event within 2 years while taking maximum tolerated statin-based therapy, an even lower LDL-C goal of <1.0 mmol/L (40 mg/dL) may be considered.\n   - The guidelines also mention that there are no differences in the RR reductions between men and women and between younger and older patients (at least up to age 75 years), or between those with and without DM when it comes to LDL-C targets.\n\n3. **Key Findings**:\n   - The causal role of LDL-C and other apoB-containing lipoproteins in ASCVD development is confirmed by genetic, observational, and intervention studies.\n   - Meta-analysis of clinical trials indicates that the relative reduction in CVD risk is proportional to the absolute reduction in LDL-C, with no evidence of a lower limit for LDL-C values or a 'J-curve' effect.\n   - The absolute benefit of lowering LDL-C depends on the absolute risk of ASCVD and the absolute reduction in LDL-C. Even small absolute reductions in LDL-C may translate to significant absolute risk reduction in high- or very-high-risk patients.\n\n4. **Recent Evidence**:\n   - A recent LDL-C target-driven RCT in patients after ischaemic stroke or transient ischaemic attack (TIA) demonstrated that a target LDL-C level of <1.8 mmol/L (70 mg/dL) with the use of statin and, if required, ezetimibe, was associated with a lower CVD risk than those who had a target range of 2.3/2.8 mmol/L (90/110 mg/dL).\n\nIn summary, the recommended LDL-C goals for patients with established ASCVD are individualized based on their specific risk factors, comorbidities, and patient preferences, but generally emphasize achieving LDL-C levels as close as possible to the given targets, with consideration of achieving very low LDL-C levels (<1.0 mmol/L or 40 mg/dL) in certain high-risk scenarios. The guidelines advocate for a stepwise approach to treatment intensification, taking into account all relevant patient-specific factors.",
      "ground_truth": "In patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a \u00e2\u2030\u00a550% reduction of LDL-C vs. baseline is recommended.",
      "context": "o fn o n - H D L - Ca sat r e a t m e n tt a r g e ta si tc a p t u r e st h ei n f o r m a t i o n\nregarding all apolipoprotein-B-containing lipoproteins.\n513 We suggest\nit as a reasonable alternative treatment goal for all patients, particularly\nfor those with hypertriglyceridaemia or DM. How non-HDL-C levels\ncorrespond to commonly used LDL-C goals is shown inTable10.\n4.6.1.4 Apolipoprotein B\nApolipoprotein B provides a direct estimate of the total concentra-\ntion of atherogenic lipid particle...",
      "latency_seconds": 164.71807146072388,
      "token_count": 577.2,
      "throughput_tokens_per_sec": 3.5041692443420223,
      "cosine_similarity": 0.40748366243434153,
      "precision": 0.09090909090909091,
      "hallucination_entities": [
        "1.8 mmol/L"
      ],
      "hallucination_count": 1,
      "contradiction_count": 0,
      "entity_overlap_context": 0.5882352941176471,
      "entity_overlap_truth": 0.3333333333333333,
      "answer_length_words": 444,
      "ground_truth_length_words": 27,
      "length_ratio": 16.444444444444443,
      "has_hallucination": true
    },
    {
      "question_id": 11,
      "question": "What is the recommended physical activity for adults to reduce all-cause mortality, CV mortality, and morbidity?",
      "answer": "Based on the provided medical documents, it is recommended for adults of all ages to strive for at least 150 - 300 minutes a week of moderate-intensity or 75 - 150 minutes a week of vigorous-intensity aerobic PA, or an equivalent combination thereof, to reduce all-cause mortality, CV mortality, and morbidity. This recommendation is supported by various studies and systematic reviews that have shown health benefits even with lower doses of physical activity, with greater benefits observed with higher doses. The documents also emphasize the importance of reducing sedentary time and engaging in at least light activity throughout the day, as well as performing resistance exercise in addition to aerobic activity. It is further noted that lifestyle interventions such as education, behaviour-change techniques, telephone counselling, and use of consumer-based wearable activity trackers should be considered to increase PA participation. The documents also highlight that exercise is contraindicated in individuals with severe, life-threatening, and unstable conditions, including those with cardiovascular diseases like coronary artery disease, unstable angina, decompensated heart failure, active thromboembolic disease, or other high-risk cardiovascular conditions.",
      "ground_truth": "It is recommended for adults of all ages to strive for at least 150\u00e2\u20ac\u201c300 min a week of moderate-intensity or 75\u00e2\u20ac\u201c150 min a week of vigorous-intensity aerobic physical activity, or an equivalent combination thereof.",
      "context": "It is recommended for adults of all ages to strive\nfor at least 150 - 300 min a week of moderate-\nintensity or 75 - 150 min a week of vigorous-\nintensity aerobic PA, or an equivalent combina-\ntion thereof, to reduce all-cause mortality, CV\nmortality, and morbidity.\n371,372\nIA\nIt is recommended that adults who cannot per-\nform 150 min of moderate-intensity PA a week\nshould stay as active as their abilities and health\ncondition allow.\n373,374\nIB\nIt is recommended to reduce sedentary time to\nengage...",
      "latency_seconds": 70.1849422454834,
      "token_count": 230.1,
      "throughput_tokens_per_sec": 3.2784810051590174,
      "cosine_similarity": 0.383539309436536,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 2,
      "entity_overlap_context": 0.4,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 177,
      "ground_truth_length_words": 34,
      "length_ratio": 5.205882352941177,
      "has_hallucination": true
    },
    {
      "question_id": 12,
      "question": "What is the recommended maximum alcohol consumption per week for cardiovascular disease prevention?",
      "answer": "Based on the provided medical documents, the recommended maximum alcohol consumption per week for cardiovascular disease (CVD) prevention is 100 grams for individuals who drink alcohol. This recommendation is explicitly stated in the context provided:\n\n\"It is recommended to restrict alcohol consumption to a maximum of 100 g per week.\"\n\nThis guideline comes from the dietary recommendations section within the medical documents, which emphasize adopting a Mediterranean or similar diet and reducing salt intake to lower blood pressure (BP) and risk of CVD. Alcohol consumption is mentioned as part of the dietary advice, with a clear limit specified for its consumption to minimize cardiovascular risk.\n\nThe context also mentions that while there is some observational evidence suggesting a J-shaped relationship between alcohol consumption and cardiovascular risk, meaning moderate consumption might have some protective effects but excessive consumption increases risk, the documents do not recommend alcohol for cardioprotection due to the lack of randomized clinical trials supporting such a recommendation. Instead, they advise abstaining from alcohol or limiting intake to 100 grams per week for those who choose to drink.\n\nThe documents further highlight that excessive alcohol use and binge drinking are associated with increased morbidity and mortality rates in patients with cardiovascular diseases (CVD), and that alcohol consumption may increase serum triglycerides. Additionally, the documents warn of potential drug-drug interactions with cardiovascular therapies when alcohol is consumed.",
      "ground_truth": "It is recommended to restrict alcohol consumption to a maximum of 100 g per week.",
      "context": "108). \nI A \n6. Adult men and women with elevated BP or hypertension who currently \nconsume alcohol should be advised to drink no more than 2 and 1 standard \ndrinks* per day, respectively (109-114). \nI \nSBP:   \nA \n7. Use of BP-lowering medications is recommended for secondary prevention \nof recurrent CVD events in patients with clinical CVD and an average SBP of \n130 mm Hg or higher or  an average DBP of 80 mm Hg or higher, and  for \nprimary prevention in adults with an estimated 10 -year atheros...",
      "latency_seconds": 75.61044144630432,
      "token_count": 295.1,
      "throughput_tokens_per_sec": 3.9029001068532168,
      "cosine_similarity": 0.4362929872395581,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.0,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 227,
      "ground_truth_length_words": 15,
      "length_ratio": 15.133333333333333,
      "has_hallucination": false
    },
    {
      "question_id": 13,
      "question": "According to the 2020 ACC/AHA guidelines, what are the stages of valvular heart disease and their definitions?",
      "answer": "Based on the provided medical documents, I don't have specific information about the stages of valvular heart disease and their definitions directly stated within the given context. However, the documents discuss various aspects of valvular heart disease including its evaluation, management strategies, and recommendations for specific conditions such as heart failure (HF) and prevention strategies.\n\nThe stages of valvular heart disease are typically classified based on the severity of valve dysfunction and the impact on ventricular function and pulmonary circulation. The stages are:\n\n1. **Stage A:** Asymptomatic with valve abnormalities detected by physical examination or echocardiography.\n2. **Stage B:** Mild to moderate symptoms, including mild valvular regurgitation or stenosis, with no signs of heart failure or ventricular dysfunction.\n3. **Stage C:** Moderate to severe symptoms, including signs of heart failure or ventricular dysfunction due to valvular disease.\n4. **Stage D:** Severe valvular disease with symptoms of severe heart failure, ventricular dysfunction, or both, often requiring surgical or interventional treatment.\n\nThe severity within these stages is further defined by the presence and degree of valve dysfunction, ventricular response to the valvular lesion, and signs of pulmonary hypertension or systemic congestion.\n\nFor detailed definitions and criteria for staging, one would need to refer to specific guidelines such as the 2021 valvular heart disease guideline (4) mentioned in the context, which may provide more detailed staging criteria based on clinical symptoms, valve anatomy, and ventricular function.\n\nThe documents emphasize the importance of a thorough patient history, physical examination, and noninvasive testing (such as echocardiography) to accurately classify the stage of valvular heart disease and guide treatment decisions. Further diagnostic steps may include more advanced imaging techniques or cardiac catheterization if initial tests show discordance between clinical findings and noninvasive testing.\n\nThe provided context focuses on management strategies for various aspects of valvular heart disease, including prevention of heart failure, treatment options for specific conditions like MR and HF, and recommendations for managing complications such as cardiac amyloidosis, cardio-oncology, and implantable devices. It does not explicitly detail the staging system but relies on established clinical practices to assess and manage patients with valvular heart disease effectively.",
      "ground_truth": "- Stage A (At risk): Patients with risk factors for developing VHD\n- Stage B (Progressive): Patients with progressive VHD (mild to moderate severity and asymptomatic)\n- Stage C (Asymptomatic severe): Asymptomatic patients who meet criteria for severe VHD\n  + C1: Asymptomatic patients with severe VHD in whom the LV or RV remains compensated\n  + C2: Asymptomatic patients with severe VHD with decompensation of LV or RV\n- Stage D (Symptomatic severe): Patients who have developed symptoms as a result of VHD",
      "context": "Top 10 Take Home Messages \n1. Disease stages in patients with valvular heart \ndise\nase should be classified (Stages A, B, C, \nand D) on the basis of symptoms, valve \nanatomy, the severity of valve dysfunction, \nand the response of the ventricle and \npulmonary circulation.\n6\n\nTop 10 Take Home Messages \n2. In the evaluation of a patient with valvular heart disease, history and \nphysical examination findings should be correlated with the results of \nnoninvasive testing (i.e., ECG, chest x-ray, tran...",
      "latency_seconds": 110.74362707138062,
      "token_count": 457.6,
      "throughput_tokens_per_sec": 4.1320662154676455,
      "cosine_similarity": 0.20795147878722603,
      "precision": 0.0,
      "hallucination_entities": [
        "heart failure",
        "hypertension"
      ],
      "hallucination_count": 2,
      "contradiction_count": 0,
      "entity_overlap_context": 0.0,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 352,
      "ground_truth_length_words": 82,
      "length_ratio": 4.2926829268292686,
      "has_hallucination": true
    },
    {
      "question_id": 14,
      "question": "In patients with atrial fibrillation and valvular heart disease, what is the recommended anticoagulation for those with rheumatic mitral stenosis or a mechanical prosthesis?",
      "answer": "Based on the provided medical documents:\n\nFor patients with atrial fibrillation and valvular heart disease, specifically those with rheumatic mitral stenosis or a mechanical prosthesis, the recommended anticoagulation is oral anticoagulation with a vitamin K antagonist (VKA). This recommendation is explicitly stated in the COR LOE Recommendations section 3 under \"Anticoagulation for AF in Patients With VHD\":\n\n\"3. For patients with AF and rheumatic mitral stenosis [MS] or a mechanical prosthesis and atrial fibrillation, oral anticoagulation with a vitamin K antagonist is recommended.\"\n\nThis recommendation is based on the need to prevent thromboembolic events while considering the specific risks associated with rheumatic mitral stenosis and the use of mechanical prostheses. VKAs are preferred over non-vitamin K antagonists (NOACs) in this scenario due to the higher risk of bleeding complications that may arise from NOACs in patients with mechanical heart valves or those with rheumatic valvular disease, as indicated in recommendation 4:\n\n\"4. In patients with mechanical heart valves with or without AF who require long-term anticoagulation with VKA to prevent valve thrombosis, NOACs are not recommended.\"\n\nTherefore, for patients with atrial fibrillation and valvular heart disease, rheumatic mitral stenosis, and a mechanical prosthesis, the recommended anticoagulation is oral VKA therapy.",
      "ground_truth": "Oral anticoagulation with a vitamin K antagonist is recommended.",
      "context": "Antithrombotic Therapy for Prosthetic Valves\nCOR LOE Recommendations\n1 A\n1. In patients with a mechanical prosthetic valve, anticoagulation with a VKA is\nrecommended.\n1 B-NR\n2. For patients with a mechanical bileaflet or current-generation single-tilting disk AV R\nand no risk factors for thromboembolism, anticoagulation with a VKA to achieve an\nINR of 2.5 is recommended.\n1 B-NR\n3. For patients with a mechanical AV Rand additional risk factors for thromboembolism\n(e.g., AF, previous thromboemboli...",
      "latency_seconds": 66.48133993148804,
      "token_count": 260.0,
      "throughput_tokens_per_sec": 3.910871836637792,
      "cosine_similarity": 0.3870433162468412,
      "precision": 0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 1,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 200,
      "ground_truth_length_words": 9,
      "length_ratio": 22.22222222222222,
      "has_hallucination": true
    },
    {
      "question_id": 15,
      "question": "According to the guidelines, what are the indications for transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR)?",
      "answer": "Based on the provided medical documents, the indications for transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) are as follows:\n\n1. **For patients with B AV and severe AS who meet criteria for AV R**: TAVI may be considered as an alternative to SAVR after consideration of patient-specific procedural risks, values, trade-offs, and preferences, especially when the surgery is performed at a Comprehensive Valve Center. This recommendation is supported by evidence from multiple randomized trials comparing TAVI to SAVR in patients with severe aortic stenosis.\n\n2. **For patients with B AV and symptomatic, severe AS**: TAVI can be considered as an alternative to SAVR when the surgery is performed at a Comprehensive Valve Center. This consideration aligns with the need for a shared decision-making process that evaluates procedural risks, patient values, and preferences.\n\n3. **For patients <50 years of age who do not have a contraindication to anticoagulation and require AV R**: It is reasonable to choose a mechanical aortic prosthesis over a bioprosthetic valve. This recommendation is based on the potential benefits and risks associated with anticoagulant therapy and the need for future valve reintervention.\n\nIn summary, the indications for TAVI versus SAVR are nuanced and depend on patient-specific factors such as age, comorbidities, procedural risks, and patient preferences. The choice should be made through a shared decision-making process that considers the latest evidence from clinical trials and the potential long-term outcomes associated with each intervention type.",
      "ground_truth": "- For patients <65 years or life expectancy >20 years: SAVR recommended\n- For patients 65-80 years: Either SAVR or transfemoral TAVI after shared decision-making\n- For patients >80 years or life expectancy <10 years: Transfemoral TAVI recommended in preference to SAVR\n- For high/prohibitive surgical risk: TAVI recommended if predicted survival >12 months",
      "context": "Top 10 Take Home Messages \n6. Indications for transcatheter aortic valve implantation are \nexpanding as a result of multiple randomized trials of \ntranscatheter aortic valve implantation atrio versus surgical \naortic valve replacement.  The choice of type of intervention for \na patient with severe aortic stenosis should be a shared decision-\nmaking process that considers the lifetime risks and benefits \nassociated with type of valve (mechanical versus bioprosthetic) \nand type of approach (transc...",
      "latency_seconds": 69.69390416145325,
      "token_count": 313.3,
      "throughput_tokens_per_sec": 4.495371636437638,
      "cosine_similarity": 0.18739026546981108,
      "precision": 0.5,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.6666666666666666,
      "entity_overlap_truth": 0.2857142857142857,
      "answer_length_words": 241,
      "ground_truth_length_words": 54,
      "length_ratio": 4.462962962962963,
      "has_hallucination": false
    },
    {
      "question_id": 16,
      "question": "What is the recommended management for asymptomatic patients with chronic severe aortic regurgitation and normal LV systolic function (Stage C1)?",
      "answer": "Based on the provided medical documents:\n\nFor asymptomatic patients with chronic severe aortic regurgitation (AR) and normal LV systolic function (Stage C1), the recommended management is as follows:\n\n1. **Aortic Valve Surgery**: In this stage, if there are no other causes for systolic dysfunction identified and the patient has severe AR (Stage C2 criteria could also apply due to the mention of \"chronic severe AR\"), aortic valve surgery is indicated. This is because surgical intervention is advised in asymptomatic patients with chronic severe AR and normal LV systolic function when there is no other identifiable cause for systolic dysfunction, especially if they meet the criteria for Stage C2 (severe AR) which includes having an indexed LVESD >25 mm/m2.\n\n2. **Medical Therapy**: While the documents specifically mention that in asymptomatic patients with primary mitral regurgitation and normal LV systolic function, vasodilator therapy is not indicated if the patient is normotensive, there is no specific mention of medical therapy for asymptomatic patients with chronic severe AR and normal LV systolic function. However, it's implied that surgical intervention is the preferred option due to the severity of AR and the lack of other identifiable causes for systolic dysfunction.\n\n3. **Monitoring**: Even if surgery is not performed immediately, these patients should be closely monitored for signs of progression or worsening of their condition, including changes in LVEF, LV dilation, and overall cardiac function. This monitoring would help in making a timely decision regarding the need for intervention.\n\nIn summary, for asymptomatic patients with chronic severe AR and normal LV systolic function (Stage C1), aortic valve surgery is recommended due to the severity of the AR and the lack of other identifiable causes for systolic dysfunction. Medical therapy, if indicated, would likely be focused on managing symptoms or complications that arise from the underlying heart disease, but specific medical treatments are not detailed in the provided context for this scenario.",
      "ground_truth": "- Aortic valve surgery is indicated if undergoing cardiac surgery for other indications\n- In patients with low surgical risk, surgery may be considered with progressive decline in LVEF to 55-60% on \u00e2\u2030\u00a53 studies or progressive LV dilation (LVEDD >65 mm)",
      "context": "Timing of Intervention for Patients with Chronic AR\nCOR LOE Recommendations\n1 B-NR 1. In symptomatic patients with severe AR (Stage D), aortic valve surgery\nis indicated regardless of LV systolic function.\n1 B-NR\n2. In asymptomatic patients with chronic severe AR and LV systolic\ndysfunction (LVEF \u226455%) (Stage C2), aortic valve surgery is indicated\nif no other cause for systolic dysfunction is identified.\n1 C-EO 3. In patients with severe AR (Stage C or D) who are undergoing cardiac\nsurgery for o...",
      "latency_seconds": 84.68983888626099,
      "token_count": 409.5,
      "throughput_tokens_per_sec": 4.835290813930597,
      "cosine_similarity": 0.2527205437232956,
      "precision": 1.0,
      "hallucination_entities": [],
      "hallucination_count": 0,
      "contradiction_count": 0,
      "entity_overlap_context": 0.5,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 315,
      "ground_truth_length_words": 41,
      "length_ratio": 7.682926829268292,
      "has_hallucination": false
    },
    {
      "question_id": 17,
      "question": "For an adult patient with hypertension and chronic kidney disease, what blood pressure treatment goal is recommended in the 2017 ACC/AHA guideline, as adapted in the 2019 document?",
      "answer": "Based on the provided medical documents from the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults and its adaptation in the 2019 document, the recommended blood pressure treatment goal for an adult patient with hypertension and chronic kidney disease (CKD) is less than 130/80 mm Hg.\n\nThis recommendation is explicitly stated in point 9 of the provided context:\n\n\"SBP: B-RSR DBP: C-EO I SBP: B-RSR 9. Adults with hypertension and CKD should be treated to a BP goal of less than 130/80 mm Hg (128-133).\"\n\nThe guideline emphasizes the importance of managing blood pressure in patients with CKD due to their increased risk of cardiovascular events, including heart attacks and strokes. The target of less than 130/80 mm Hg is a conservative approach to reduce the risk of these events while considering the potential for reduced kidney function to impact the efficacy of antihypertensive medications and the need to balance blood pressure control with the risk of hypotension and worsening renal function.\n\nThe guideline also highlights that treatment goals should be individualized based on the patient's overall cardiovascular risk profile, including the presence of diabetes mellitus (DM) as mentioned in point 10, which further emphasizes the importance of a tailored approach to BP management in patients with comorbid conditions such as CKD and DM.",
      "ground_truth": "Treatment to a BP goal of less than 130/80 mm Hg is recommended.",
      "context": "18 \n \nI \nSBP:  \nB-RSR \n4. In adults with hypertension and chronic kidney disease, treatment to a BP goal of \nless than 130/80 mm Hg is recommended (128-133).  \n \nAdapted from recommendations in the 2017 \nACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the \nPrevention, Detection, Evaluation, and Management of High Blood Pressure in Adults \n(12). \nDBP:  \nC-EO \nI \nSBP:  \nB-RSR \n5. In adults with T2DM and hypertension, antihypertensive drug treatment should be \ninitiated at a BP of 13...",
      "latency_seconds": 88.6854510307312,
      "token_count": 288.6,
      "throughput_tokens_per_sec": 3.25419780410199,
      "cosine_similarity": 0.30992822866284736,
      "precision": 0,
      "hallucination_entities": [
        "diabetes"
      ],
      "hallucination_count": 1,
      "contradiction_count": 0,
      "entity_overlap_context": 0.3333333333333333,
      "entity_overlap_truth": 0.0,
      "answer_length_words": 222,
      "ground_truth_length_words": 13,
      "length_ratio": 17.076923076923077,
      "has_hallucination": true
    },
    {
      "question_id": 18,
      "question": "For primary prevention in a 40-75 year old adult with diabetes mellitus, what intensity of statin therapy is recommended by the 2018 Cholesterol Guideline, regardless of their estimated 10-year ASCVD risk?",
      "answer": "Based on the provided medical documents from the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol, for primary prevention in a 40-75 year old adult with diabetes mellitus, regardless of their estimated 10-year ASCVD risk, the recommended intensity of statin therapy is moderate-intensity. This recommendation is explicitly stated in section I.A of the guideline:\n\n1. In adults at intermediate-risk (\u22657.5% to <20% 10-year ASCVD risk), statin therapy reduces risk of ASCVD, and in the context of a risk discussion, if a decision is made for statin therapy, a moderate-intensity statin should be recommended (148-155).\n\nThis guideline emphasizes the importance of considering the patient's risk level when prescribing statin therapy. For individuals with diabetes mellitus, the guideline suggests a stepwise approach to lipid control based on risk, estimated lifetime benefit, comorbidities, and patient preferences. However, for primary prevention in adults 40 to 75 years of age with diabetes, regardless of their specific 10-year ASCVD risk level, moderate-intensity statin therapy is recommended due to the consistent association between lowering LDL-C levels and lower CVD risk in these patients.\n\nThe guideline does not specify a different intensity of statin therapy for individuals with diabetes mellitus who are at intermediate risk compared to those at higher or lower risk within this age group. Therefore, based solely on the provided medical documents, moderate-intensity statin therapy is the recommended approach for primary prevention in a 40-75 year old adult with diabetes mellitus, irrespective of their estimated 10-year ASCVD risk.",
      "ground_truth": "Moderate-intensity statin therapy is indicated.",
      "context": "or more (148, 151-156). \nAdapted from recommendations in the 2018 \nAHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the \nManagement of Blood Cholesterol (9). \nI A \n3. In adults 40 to 75 years of age with diabetes, regardless of estimated 10-year ASCVD \nrisk, moderate-intensity statin therapy is indicated (157-165).  \nIncluded from recommendations in the 2018 \nAHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the \nManagement of Blood Cholesterol (9). \nI B-R ...",
      "latency_seconds": 104.03945302963257,
      "token_count": 317.2,
      "throughput_tokens_per_sec": 3.0488434027969653,
      "cosine_similarity": 0.2483319226353816,
      "precision": 0.2,
      "hallucination_entities": [
        "75 year"
      ],
      "hallucination_count": 1,
      "contradiction_count": 1,
      "entity_overlap_context": 0.2,
      "entity_overlap_truth": 1.0,
      "answer_length_words": 244,
      "ground_truth_length_words": 5,
      "length_ratio": 48.8,
      "has_hallucination": true
    }
  ]
}